Accessing	O
Epstein-Barr	O
virus-specific	O
T-cell	O
memory	O
with	O
peptide-loaded	B-cell_line
dendritic	I-cell_line
cells	I-cell_line
.	O

The	O
conventional	O
means	O
of	O
studying	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
-induced	O
cytotoxic	B-cell_type
T-lymphocyte	I-cell_type
(	O
CTL	O
)	O
memory	O
,	O
by	O
in	O
vitro	O
stimulation	O
with	O
the	O
latently	O
infected	O
autologous	O
lymphoblastoid	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
LCL	B-cell_line
)	O
,	O
has	O
important	O
limitations	O
.	O

First	O
,	O
it	O
gives	O
no	O
information	O
on	O
memory	O
to	O
lytic	B-protein
cycle	I-protein
antigens	I-protein
;	O
second	O
,	O
it	O
preferentially	O
amplifies	O
the	O
dominant	O
components	O
of	O
latent	O
antigen-specific	O
memory	O
at	O
the	O
expense	O
of	O
key	O
subdominant	O
reactivities	O
.	O

Here	O
we	O
describe	O
an	O
alternative	O
approach	O
,	O
based	O
on	O
in	O
vitro	O
stimulation	O
with	O
epitope	B-cell_line
peptide-loaded	I-cell_line
dendritic	I-cell_line
cells	I-cell_line
(	O
DCs	B-cell_line
)	O
,	O
which	O
allows	O
one	O
to	O
probe	O
the	O
CTL	O
repertoire	O
for	O
any	O
individual	O
reactivity	O
of	O
choice	O
;	O
this	O
method	O
proved	O
significantly	O
more	O
efficient	O
than	O
stimulation	O
with	O
peptide	O
alone	O
.	O

Using	O
this	O
approach	O
we	O
first	O
show	O
that	O
reactivities	O
to	O
the	O
immunodominant	O
and	O
subdominant	O
lytic	B-protein
cycle	I-protein
epitopes	I-protein
identified	O
by	O
T	B-cell_type
cells	I-cell_type
during	O
primary	O
EBV	O
infection	O
are	O
regularly	O
detectable	O
in	O
the	O
CTL	O
memory	O
of	O
virus	O
carriers	O
;	O
this	O
implies	O
that	O
in	O
such	O
carriers	O
chronic	O
virus	O
replication	O
remains	O
under	O
direct	O
T-cell	O
control	O
.	O

We	O
further	O
show	O
that	O
subdominant	O
latent	O
cycle	O
reactivities	O
to	O
epitopes	O
in	O
the	O
latent	B-protein
membrane	I-protein
protein	I-protein
LMP2	I-protein
,	O
though	O
rarely	O
undetectable	O
in	O
LCL	B-cell_line
-stimulated	O
populations	O
,	O
can	O
be	O
reactivated	O
by	O
DC	O
stimulation	O
and	O
selectively	O
expanded	O
as	O
polyclonal	O
CTL	B-cell_line
lines	I-cell_line
;	O
the	O
adoptive	O
transfer	O
of	O
such	O
preparations	O
may	O
be	O
of	O
value	O
in	O
targeting	O
certain	O
EBV-positive	O
malignancies	O
.	O

JOURNAL	NULL
or	NULL
ViROLOGY	NULL
,	NULL
Jan.	NULL
1999	NULL
,	NULL
p.	NULL
334-342	NULL
0022-538	NULL
X/99/	NULL
$	NULL
04.00+0	NULL
Vol	NULL
.	NULL

73	NULL
,	NULL
No	NULL
.	NULL

1	NULL
Copyright	NULL
©	NULL
1999	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
.	NULL

All	NULL
Rights	NULL
Reserved	NULL
.	NULL

Accessing	NULL
Epstein-Barr	NULL
Virus-Specific	NULL
T-Cell	NULL
Memory	NULL
with	NULL
Peptide-Loaded	NULL
Dendritic	NULL
Cells	NULL
I.	NULL
V.	NULL
REDCHENKO	NULL
anp	NULL
A	NULL
.	NULL

B.	NULL
RICKINSON®*	NULL
CRC	NULL
Institute	NULL
for	NULL
Cancer	NULL
Studies	NULL
,	NULL
University	NULL
of	NULL
Birmingham	NULL
,	NULL
Edgbaston	NULL
,	NULL
Birmingham	NULL
,	NULL
B15	NULL
2TA	NULL
United	NULL
Kingdom	NULL
Received	NULL
20	NULL
July	NULL
1998/Accepted	NULL
17	NULL
September	NULL
1998	NULL
The	NULL
conventional	NULL
means	NULL
of	NULL
studying	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
-induced	NULL
cytotoxic	NULL
T-lymphocyte	NULL
(	NULL
CTL	NULL
)	NULL
mem-ory	NULL
,	NULL
by	NULL
in	NULL
vitro	NULL
stimulation	NULL
with	NULL
the	NULL
latently	NULL
infected	NULL
autologous	NULL
lymphoblastoid	NULL
cell	NULL
line	NULL
(	NULL
LCL	NULL
)	NULL
,	NULL
has	NULL
important	NULL
limitations	NULL
.	NULL

First	NULL
,	NULL
it	NULL
gives	NULL
no	NULL
information	NULL
on	NULL
memory	NULL
to	NULL
lytic	NULL
cycle	NULL
antigens	NULL
;	NULL
second	NULL
,	NULL
it	NULL
preferentially	NULL
amplifies	NULL
the	NULL
dominant	NULL
components	NULL
of	NULL
latent	NULL
antigen-specific	NULL
memory	NULL
at	NULL
the	NULL
expense	NULL
of	NULL
key	NULL
subdominant	NULL
reactivities	NULL
.	NULL

Here	NULL
we	NULL
describe	NULL
an	NULL
alternative	NULL
approach	NULL
,	NULL
based	NULL
on	NULL
in	NULL
vitro	NULL
stimulation	NULL
with	NULL
epitope	NULL
peptide-loaded	NULL
dendritic	NULL
cells	NULL
(	NULL
DCs	NULL
)	NULL
,	NULL
which	NULL
allows	NULL
one	NULL
to	NULL
probe	NULL
the	NULL
CTL	NULL
repertoire	NULL
for	NULL
any	NULL
individual	NULL
reactivity	NULL
of	NULL
choice	NULL
;	NULL
this	NULL
method	NULL
proved	NULL
significantly	NULL
more	NULL
efficient	NULL
than	NULL
stimulation	NULL
with	NULL
peptide	NULL
alone	NULL
.	NULL

Using	NULL
this	NULL
approach	NULL
we	NULL
first	NULL
show	NULL
that	NULL
reactivities	NULL
to	NULL
the	NULL
immunodominant	NULL
and	NULL
subdominant	NULL
lytic	NULL
cycle	NULL
epitopes	NULL
identified	NULL
by	NULL
T	NULL
cells	NULL
during	NULL
primary	NULL
EBV	NULL
infection	NULL
are	NULL
regularly	NULL
detectable	NULL
in	NULL
the	NULL
CTL	NULL
memory	NULL
of	NULL
virus	NULL
carriers	NULL
;	NULL
this	NULL
implies	NULL
that	NULL
in	NULL
such	NULL
carriers	NULL
chronic	NULL
virus	NULL
replication	NULL
remains	NULL
under	NULL
direct	NULL
T-cell	NULL
control	NULL
.	NULL

We	NULL
further	NULL
show	NULL
that	NULL
subdominant	NULL
latent	NULL
cycle	NULL
reactivities	NULL
to	NULL
epitopes	NULL
in	NULL
the	NULL
latent	NULL
membrane	NULL
protein	NULL
LMP2	NULL
,	NULL
though	NULL
rarely	NULL
undetectable	NULL
in	NULL
LCL-stimulated	NULL
populations	NULL
,	NULL
can	NULL
be	NULL
reactivated	NULL
by	NULL
DC	NULL
stimulation	NULL
and	NULL
selectively	NULL
expanded	NULL
as	NULL
polyclonal	NULL
CTL	NULL
lines	NULL
;	NULL
the	NULL
adoptive	NULL
transfer	NULL
of	NULL
such	NULL
preparations	NULL
may	NULL
be	NULL
of	NULL
value	NULL
in	NULL
targeting	NULL
certain	NULL
EBV-positive	NULL
malignancies	NULL
.	NULL

Cytotoxic	NULL
T	NULL
lymphocytes	NULL
(	NULL
CTLs	NULL
)	NULL
of	NULL
CD8*	NULL
type	NULL
recognize	NULL
peptides	NULL
derived	NULL
from	NULL
the	NULL
intracellular	NULL
breakdown	NULL
of	NULL
foreign	NULL
antigens	NULL
and	NULL
presented	NULL
at	NULL
the	NULL
cell	NULL
surface	NULL
as	NULL
a	NULL
complex	NULL
with	NULL
major	NULL
histocompatibility	NULL
complex	NULL
(	NULL
MHC	NULL
)	NULL
class	NULL
I	NULL
molecules	NULL
(	NULL
58	NULL
)	NULL
.	NULL

Such	NULL
CTLs	NULL
appear	NULL
to	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
controlling	NULL
virus	NULL
infection	NULL
.	NULL

Even	NULL
with	NULL
genetically	NULL
complex	NULL
viruses	NULL
,	NULL
however	NULL
,	NULL
the	NULL
virus-induced	NULL
CTL	NULL
response	NULL
tends	NULL
to	NULL
focus	NULL
on	NULL
a	NULL
few	NULL
immunodominant	NULL
peptide	NULL
epitopes	NULL
whose	NULL
identities	NULL
are	NULL
specific	NULL
for	NULL
the	NULL
particular	NULL
MHC	NULL
type	NULL
of	NULL
the	NULL
host	NULL
.	NULL

The	NULL
present	NULL
study	NULL
concerns	NULL
the	NULL
CTL	NULL
response	NULL
to	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
,	NULL
a	NULL
human	NULL
herpesvirus	NULL
with	NULL
cell	NULL
growth	NULL
transforming	NULL
ability	NULL
which	NULL
is	NULL
linked	NULL
to	NULL
several	NULL
malignancies	NULL
and	NULL
yet	NULL
is	NULL
carried	NULL
by	NULL
most	NULL
individuals	NULL
as	NULL
an	NULL
asymptomatic	NULL
lifelong	NULL
infection	NULL
.	NULL

Virus	NULL
carriage	NULL
is	NULL
characterized	NULL
by	NULL
latent	NULL
infection	NULL
of	NULL
the	NULL
B	NULL
lymphocyte	NULL
pool	NULL
and	NULL
by	NULL
chronic	NULL
shedding	NULL
of	NULL
infectious	NULL
virus	NULL
from	NULL
productively	NULL
infected	NULL
cells	NULL
within	NULL
the	NULL
oropharynx	NULL
(	NULL
37	NULL
)	NULL
.	NULL

The	NULL
repertoire	NULL
of	NULL
EBV-specific	NULL
T	NULL
cells	NULL
in	NULL
virus	NULL
carriers	NULL
is	NULL
conventionally	NULL
studied	NULL
by	NULL
challenging	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
in	NULL
vitro	NULL
with	NULL
cells	NULL
of	NULL
the	NULL
autologous	NULL
EBV-transformed	NULL
B	NULL
lymphoblastoid	NULL
cell	NULL
line	NULL
(	NULL
LCL	NULL
)	NULL
(	NULL
38	NULL
)	NULL
.	NULL

However	NULL
,	NULL
this	NULL
approach	NULL
has	NULL
at	NULL
least	NULL
two	NULL
important	NULL
limitations	NULL
.	NULL

First	NULL
,	NULL
because	NULL
LCLs	NULL
are	NULL
largely	NULL
composed	NULL
of	NULL
latently	NULL
infected	NULL
cells	NULL
,	NULL
LCL	NULL
stimulation	NULL
tells	NULL
us	NULL
very	NULL
little	NULL
about	NULL
CTL	NULL
responses	NULL
to	NULL
antigens	NULL
of	NULL
the	NULL
virus	NULL
lytic	NULL
cycle	NULL
.	NULL

In	NULL
consequence	NULL
,	NULL
the	NULL
latter	NULL
issue	NULL
was	NULL
largely	NULL
,	NULL
if	NULL
not	NULL
completely	NULL
(	NULL
8	NULL
)	NULL
,	NULL
ignored	NULL
until	NULL
recently	NULL
when	NULL
analysis	NULL
of	NULL
the	NULL
in	NULL
vivo-activated	NULL
primary	NULL
response	NULL
to	NULL
EBV	NULL
in	NULL
infectious	NULL
mononucleosis	NULL
patients	NULL
showed	NULL
that	NULL
lytic-cycle-specific	NULL
reactivities	NULL
not	NULL
only	NULL
existed	NULL
but	NULL
were	NULL
unusually	NULL
strong	NULL
and	NULL
could	NULL
be	NULL
mapped	NULL
to	NULL
defined	NULL
epitopes	NULL
within	NULL
immediate-early/early-lytic	NULL
proteins	NULL
(	NULL
14	NULL
,	NULL
49	NULL
)	NULL
.	NULL

It	NULL
is	NULL
important	NULL
now	NULL
to	NULL
develop	NULL
methods	NULL
of	NULL
probing	NULL
T	NULL
cell	NULL
memory	NULL
to	NULL
determine	NULL
whether	NULL
such	NULL
reactivities	NULL
persist	NULL
in	NULL
the	NULL
longer	NULL
term	NULL
.	NULL

A	NULL
second	NULL
potential	NULL
limitation	NULL
of	NULL
the	NULL
LCL	NULL
stimulation	NULL
protocol	NULL
stems	NULL
from	NULL
the	NULL
marked	NULL
skewing	NULL
of	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
CRC	NULL
Institute	NULL
for	NULL
Cancer	NULL
Studies	NULL
,	NULL
University	NULL
of	NULL
Birmingham	NULL
,	NULL
Edgbaston	NULL
,	NULL
Birmingham	NULL
,	NULL
B15	NULL
2TA	NULL
United	NULL
Kingdom	NULL
.	NULL

Phone	NULL
:	NULL
121-414-4492	NULL
.	NULL

Fax	NULL
:	NULL
121-414-4486	NULL
.	NULL

E-mail	NULL
:	NULL
Williamsd	NULL
@	NULL
cancer.bham.ac.uk	NULL
.	NULL

334	NULL
the	NULL
latent	NULL
antigen-specific	NULL
response	NULL
towards	NULL
a	NULL
particular	NULL
subset	NULL
of	NULL
latent	NULL
proteins	NULL
.	NULL

Thus	NULL
,	NULL
while	NULL
LCL	NULL
cells	NULL
express	NULL
all	NULL
six	NULL
EBV-coded	NULL
nuclear	NULL
antigens	NULL
EBNA1	NULL
,	NULL
-2	NULL
,	NULL
-3A	NULL
,	NULL
-3B	NULL
,	NULL
-3C	NULL
,	NULL
and	NULL
-LP	NULL
and	NULL
the	NULL
latent	NULL
membrane	NULL
proteins	NULL
1	NULL
and	NULL
2	NULL
(	NULL
LMP1	NULL
and	NULL
LMP2	NULL
)	NULL
,	NULL
LCL-stimulated	NULL
CTL	NULL
preparations	NULL
are	NULL
very	NULL
often	NULL
dominated	NULL
by	NULL
reactivities	NULL
to	NULL
peptide	NULL
epitopes	NULL
from	NULL
the	NULL
EBNA3A	NULL
,	NULL
-3B	NULL
,	NULL
and	NULL
-3C	NULL
proteins	NULL
(	NULL
22	NULL
,	NULL
33	NULL
)	NULL
.	NULL

Usually	NULL
it	NULL
is	NULL
only	NULL
through	NULL
single-cell	NULL
cloning	NULL
that	NULL
CTLs	NULL
recognizing	NULL
one	NULL
or	NULL
another	NULL
of	NULL
the	NULL
subdominant	NULL
latent	NULL
antigens	NULL
,	NULL
most	NULL
commonly	NULL
LMP2	NULL
,	NULL
are	NULL
detected	NULL
(	NULL
10	NULL
,	NULL
22	NULL
,	NULL
24	NULL
)	NULL
.	NULL

In	NULL
adoptive	NULL
therapy	NULL
the	NULL
above	NULL
polyclonal	NULL
CTLs	NULL
have	NULL
proven	NULL
effective	NULL
against	NULL
at	NULL
least	NULL
one	NULL
EBV-associated	NULL
malig-nancy	NULL
,	NULL
immunoblastic	NULL
lymphoma	NULL
of	NULL
immunosuppressed	NULL
subjects	NULL
(	NULL
42	NULL
)	NULL
,	NULL
where	NULL
the	NULL
tumor	NULL
cells	NULL
express	NULL
the	NULL
immunodominant	NULL
EBNA3	NULL
proteins	NULL
(	NULL
19	NULL
,	NULL
51	NULL
)	NULL
.	NULL

However	NULL
,	NULL
such	NULL
CTLs	NULL
are	NULL
unlikely	NULL
to	NULL
be	NULL
as	NULL
effective	NULL
in	NULL
the	NULL
context	NULL
of	NULL
other	NULL
malignancies	NULL
,	NULL
such	NULL
as	NULL
nasopharyngeal	NULL
carcinoma	NULL
,	NULL
where	NULL
viral	NULL
antigen	NULL
expression	NULL
is	NULL
limited	NULL
to	NULL
EBNA1	NULL
,	NULL
LMP2	NULL
,	NULL
and	NULL
in	NULL
some	NULL
cases	NULL
LMP1	NULL
(	NULL
37	NULL
)	NULL
.	NULL

Since	NULL
endogenously	NULL
expressed	NULL
EBNA1	NULL
is	NULL
protected	NULL
from	NULL
presentation	NULL
to	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
by	NULL
virtue	NULL
of	NULL
its	NULL
Gly-Ala	NULL
repeat	NULL
domain	NULL
(	NULL
7	NULL
,	NULL
25	NULL
,	NULL
26	NULL
)	NULL
,	NULL
the	NULL
LMPs	NULL
(	NULL
and	NULL
particularly	NULL
LMP2	NULL
)	NULL
constitute	NULL
potentially	NULL
important	NULL
targets	NULL
for	NULL
immune	NULL
recognition	NULL
if	NULL
polyclonal	NULL
CTL	NULL
preparations	NULL
enriched	NULL
for	NULL
such	NULL
reactivities	NULL
could	NULL
be	NULL
pro-duced	NULL
.	NULL

Against	NULL
this	NULL
background	NULL
,	NULL
we	NULL
sought	NULL
to	NULL
develop	NULL
an	NULL
efficient	NULL
protocol	NULL
for	NULL
the	NULL
selective	NULL
reactivation	NULL
of	NULL
memory	NULL
CTLs	NULL
specific	NULL
for	NULL
defined	NULL
lytic	NULL
and	NULL
subdominant	NULL
latent	NULL
cycle	NULL
epitopes	NULL
.	NULL

Dendritic	NULL
cells	NULL
(	NULL
DC	NULL
)	NULL
are	NULL
the	NULL
most	NULL
attractive	NULL
vehicles	NULL
for	NULL
this	NULL
purpose	NULL
since	NULL
they	NULL
have	NULL
proved	NULL
most	NULL
effective	NULL
as	NULL
antigen-presenting	NULL
cells	NULL
(	NULL
APCs	NULL
)	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
systems	NULL
(	NULL
5	NULL
,	NULL
21	NULL
,	NULL
28	NULL
,	NULL
29	NULL
,	NULL
31	NULL
)	NULL
.	NULL

In	NULL
vivo	NULL
,	NULL
immature	NULL
DCs	NULL
develop	NULL
from	NULL
hemato-poietic	NULL
progenitors	NULL
and	NULL
are	NULL
located	NULL
strategically	NULL
at	NULL
body	NULL
sur-faces	NULL
,	NULL
where	NULL
they	NULL
play	NULL
a	NULL
sentinel	NULL
role	NULL
in	NULL
capturing	NULL
and	NULL
processing	NULL
antigens	NULL
.	NULL

Following	NULL
antigen	NULL
exposure	NULL
,	NULL
DCs	NULL
migrate	NULL
to	NULL
lymphoid	NULL
organs	NULL
and	NULL
acquire	NULL
potent	NULL
antigen-presenting	NULL
function	NULL
with	NULL
cell	NULL
surface	NULL
upregulation	NULL
of	NULL
adhesion	NULL
molecules	NULL
such	NULL
as	NULL
CD54	NULL
(	NULL
ICAM1	NULL
)	NULL
and	NULL
of	NULL
costimulatory	NULL
molecules	NULL
such	NULL
as	NULL
CD80	NULL
and	NULL
CD86	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Human	NULL
DCs	NULL
can	NULL
be	NULL
generated	NULL
in	NULL
vitro	NULL
either	NULL
from	NULL
rare	NULL
CD34	NULL
*	NULL
cell	NULL
precursors	NULL
in	NULL
peripheral	NULL
blood	NULL
voL	NULL
.	NULL

73	NULL
,	NULL
1999	NULL
TABLE	NULL
1	NULL
.	NULL

Epitope	NULL
peptides	NULL
used	NULL
in	NULL
DC	NULL
stimulation	NULL
DENDRITIC	NULL
CELL	NULL
STIMULATION	NULL
OF	NULL
EBV-SPECIFIC	NULL
T	NULL
CELLS	NULL
|	NULL
335	NULL
Location	NULL
Epitope	NULL
type	NULL
Designation	NULL
.	NULL

Amino	NULL
Sequence	NULL
HLA	NULL
class	NULL
I	NULL
restriction	NULL
Reference	NULL
Antigen	NULL
acid	NULL
site	NULL
Immunodominant	NULL
latent-cycle	NULL
epitope	NULL
QAK	NULL
EBNA3A	NULL
158-166	NULL
_	NULL
QAKWRLOQTL	NULL
B8	NULL
38	NULL
FLR	NULL
EBNA3A	NULL
325-333	NULL
-	NULL
FLRGRAYGL	NULL
B8	NULL
2	NULL
IVT	NULL
EBNA3B	NULL
416-424	NULL
_	NULL
IVTDFSVIK	NULL
A1l1.01	NULL
18	NULL
AVF	NULL
EBNA3B	NULL
399-408	NULL
_	NULL
AVFDRKSDAK	NULL
A1l1.01	NULL
18	NULL
RRI	NULL
EBNA3C	NULL
258-266	NULL
-	NULL
RRIYDLIEL	NULL
B27.02/27.05	NULL
9	NULL
RRA	NULL
EBNA3B	NULL
244-254	NULL
_	NULL
RRARSLSAERY	NULL
B27.02	NULL
10	NULL
Subdominant	NULL
latent-cycle	NULL
epitope	NULL
LLW	NULL
LMP2	NULL
329-337	NULL
-	NULL
LLWTLVVLL	NULL
A2.01	NULL
24	NULL
CLG	NULL
LMP2	NULL
426-434	NULL
_	NULL
CLGGLLTMV	NULL
A2.01	NULL
24	NULL
IED	NULL
LMP2	NULL
200-208	NULL
_	NULL
IEDPPFNSL	NULL
B40.01	NULL
24	NULL
SSC	NULL
LMP2	NULL
340-350	NULL
_	NULL
SSCSSCPLSKI	NULL
A1l1.01	NULL
24	NULL
TYG	NULL
LMP2	NULL
419-427	NULL
_	NULL
TYGPVFMCL	NULL
A24.02	NULL
24	NULL
Lytic-cycle	NULL
epitope	NULL
APE	NULL
BZLFI	NULL
82-90	NULL
APENAYQAY	NULL
B35.01	NULL
Unpublished	NULL
RAK	NULL
BZLFI	NULL
190-197	NULL
_	NULL
RAKFKQLL	NULL
B8	NULL
8	NULL
GLC	NULL
BMLF1	NULL
280-288	NULL
-	NULL
GLCTLVAML	NULL
A2.01	NULL
49	NULL
TLD	NULL
BMRFI	NULL
208-216	NULL
_	NULL
TLDYKPLSV	NULL
A2.01	NULL
Unpublished	NULL
(	NULL
15	NULL
,	NULL
40	NULL
)	NULL
or	NULL
,	NULL
more	NULL
commonly	NULL
,	NULL
from	NULL
monocytes	NULL
by	NULL
culturing	NULL
in	NULL
medium	NULL
supplemented	NULL
with	NULL
interleukin	NULL
4	NULL
(	NULL
IL-4	NULL
)	NULL
and	NULL
granulo-cyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
GM-CSF	NULL
followed	NULL
by	NULL
maturation	NULL
stimuli	NULL
(	NULL
6	NULL
,	NULL
41	NULL
,	NULL
43	NULL
)	NULL
.	NULL

Following	NULL
reports	NULL
of	NULL
the	NULL
successful	NULL
use	NULL
of	NULL
peptide-loaded	NULL
DCs	NULL
to	NULL
induce	NULL
epitope-specific	NULL
CTL	NULL
responses	NULL
to	NULL
melanoma-associated	NULL
antigens	NULL
(	NULL
34	NULL
,	NULL
52	NULL
,	NULL
53	NULL
)	NULL
,	NULL
we	NULL
have	NULL
used	NULL
here	NULL
a	NULL
parallel	NULL
approach	NULL
in	NULL
an	NULL
attempt	NULL
to	NULL
selectively	NULL
reactivate	NULL
responses	NULL
to	NULL
defined	NULL
EBV	NULL
epitope	NULL
peptides	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Media	NULL
and	NULL
reagents	NULL
.	NULL

The	NULL
medium	NULL
used	NULL
throughout	NULL
was	NULL
RPMI	NULL
1640	NULL
(	NULL
Gibco	NULL
Laboratories	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
N.Y.	NULL
)	NULL
supplemented	NULL
with	NULL
2	NULL
mM	NULL
L-glutamine	NULL
,	NULL
100	NULL
IU	NULL
of	NULL
penicillin	NULL
per	NULL
ml	NULL
,	NULL
100	NULL
ug	NULL
of	NULL
streptomycin	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
10	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
RPMI-10	NULL
%	NULL
FCS	NULL
)	NULL
.	NULL

Human	NULL
recombinant	NULL
IL-7	NULL
and	NULL
B2-microglobulin	NULL
were	NULL
obtained	NULL
from	NULL
Sigma	NULL
.	NULL

Human	NULL
recombinant	NULL
IL-2	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Glaxo-Wellcome	NULL
(	NULL
Stevenage	NULL
,	NULL
United	NULL
Kingdom	NULL
)	NULL
,	NULL
and	NULL
human	NULL
recombinant	NULL
IL-4	NULL
and	NULL
GM-CSF	NULL
was	NULL
provided	NULL
by	NULL
Schering-Plough	NULL
(	NULL
Dardilly	NULL
,	NULL
France	NULL
)	NULL
.	NULL

Monoclonal	NULL
antibody	NULL
(	NULL
MAb	NULL
)	NULL
to	NULL
CD83	NULL
(	NULL
59	NULL
)	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
T.	NULL
Tedder	NULL
(	NULL
Duke	NULL
University	NULL
,	NULL
Durham	NULL
,	NULL
N.C.	NULL
)	NULL
;	NULL
MAbs	NULL
Bu74	NULL
to	NULL
CD54	NULL
and	NULL
Bu63	NULL
to	NULL
CD86	NULL
were	NULL
obtained	NULL
from	NULL
D.	NULL
Hardie	NULL
(	NULL
Department	NULL
of	NULL
Immunology	NULL
,	NULL
University	NULL
of	NULL
Birmingham	NULL
,	NULL
Birmingham	NULL
,	NULL
United	NULL
Kingdom	NULL
)	NULL
,	NULL
and	NULL
MAb	NULL
L307.4	NULL
to	NULL
CD80	NULL
was	NULL
obtained	NULL
from	NULL
Becton	NULL
Dickinson	NULL
(	NULL
Immunocytometry	NULL
Systems	NULL
,	NULL
Lincoln	NULL
Park	NULL
,	NULL
N.J.	NULL
)	NULL
.	NULL

Preparation	NULL
of	NULL
stimulator	NULL
and	NULL
target	NULL
cells	NULL
.	NULL

To	NULL
prepare	NULL
DCs	NULL
,	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMCs	NULL
)	NULL
were	NULL
isolated	NULL
by	NULL
centrifugation	NULL
on	NULL
Lymphoprep	NULL
(	NULL
Nycomed	NULL
Pharma	NULL
,	NULL
Oslo	NULL
,	NULL
Norway	NULL
)	NULL
,	NULL
resuspended	NULL
in	NULL
RPMI-10	NULL
%	NULL
FCS	NULL
at	NULL
5	NULL
x	NULL
10°	NULL
cells/ml	NULL
,	NULL
and	NULL
seeded	NULL
into	NULL
6-well	NULL
plates	NULL
(	NULL
Costar	NULL
Corp.	NULL
,	NULL
Cambridge	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

at	NULL
10	NULL
``	NULL
cells/well	NULL
.	NULL

After	NULL
2	NULL
h	NULL
at	NULL
37°C	NULL
,	NULL
nonadherent	NULL
cells	NULL
were	NULL
removed	NULL
,	NULL
and	NULL
the	NULL
adherent	NULL
cell	NULL
population	NULL
was	NULL
cultured	NULL
in	NULL
RPMI-10	NULL
%	NULL
FCS	NULL
supplemented	NULL
with	NULL
50	NULL
ng	NULL
of	NULL
GM-CSF	NULL
and	NULL
1,000	NULL
U	NULL
of	NULL
IL-4	NULL
per	NULL
ml	NULL
.	NULL

The	NULL
cultures	NULL
were	NULL
refed	NULL
on	NULL
days	NULL
2	NULL
and	NULL
4	NULL
by	NULL
replacing	NULL
half	NULL
of	NULL
the	NULL
medium	NULL
with	NULL
fresh	NULL
medium	NULL
as	NULL
described	NULL
above	NULL
;	NULL
on	NULL
day	NULL
6	NULL
the	NULL
culture	NULL
medium	NULL
was	NULL
changed	NULL
to	NULL
fresh	NULL
RPMI-10	NULL
%	NULL
FCS	NULL
with	NULL
GM-CSF	NULL
and	NULL
IL-4	NULL
as	NULL
described	NULL
above	NULL
,	NULL
but	NULL
now	NULL
supplemented	NULL
with	NULL
25	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
macrophage-conditioned	NULL
medium	NULL
(	NULL
see	NULL
below	NULL
)	NULL
as	NULL
a	NULL
maturation	NULL
stimulus	NULL
.	NULL

Nonadherent	NULL
cells	NULL
were	NULL
harvested	NULL
2	NULL
days	NULL
later	NULL
and	NULL
used	NULL
as	NULL
a	NULL
source	NULL
of	NULL
DCs	NULL
;	NULL
the	NULL
quality	NULL
of	NULL
the	NULL
DC	NULL
preparation	NULL
was	NULL
checked	NULL
in	NULL
each	NULL
case	NULL
by	NULL
immunofluorescence	NULL
staining	NULL
for	NULL
surface	NULL
markers	NULL
CD54	NULL
,	NULL
CD80	NULL
,	NULL
CD83	NULL
,	NULL
and	NULL
CD86	NULL
by	NULL
using	NULL
specific	NULL
MAbs	NULL
.	NULL

Macrophage-conditioned	NULL
medium	NULL
was	NULL
produced	NULL
by	NULL
culturing	NULL
adherent	NULL
PBMCs	NULL
(	NULL
isolat-ed	NULL
by	NULL
adherence	NULL
to	NULL
human	NULL
immunoglobulin-coated	NULL
plates	NULL
[	NULL
40	NULL
]	NULL
)	NULL
for	NULL
24	NULL
h	NULL
at	NULL
37°C	NULL
in	NULL
RPMI-10	NULL
%	NULL
FCS	NULL
and	NULL
then	NULL
harvesting	NULL
the	NULL
supernatant	NULL
medium	NULL
,	NULL
followed	NULL
by	NULL
filtration	NULL
through	NULL
a	NULL
0.2-pm	NULL
(	NULL
pore	NULL
size	NULL
)	NULL
membrane	NULL
(	NULL
Acrodisc	NULL
;	NULL
Gelman	NULL
Sciences	NULL
)	NULL
and	NULL
storage	NULL
at	NULL
-20°C	NULL
for	NULL
up	NULL
to	NULL
8	NULL
weeks	NULL
before	NULL
use	NULL
.	NULL

As	NULL
described	NULL
elsewhere	NULL
(	NULL
50	NULL
)	NULL
,	NULL
EBV-transformed	NULL
LCLs	NULL
(	NULL
carrying	NULL
the	NULL
B95.8	NULL
or	NULL
the	NULL
BL74	NULL
virus	NULL
strain	NULL
)	NULL
and	NULL
PHA	NULL
blast	NULL
targets	NULL
were	NULL
established	NULL
and	NULL
maintained	NULL
as	NULL
a	NULL
source	NULL
of	NULL
stimulation	NULL
and/or	NULL
target	NULL
cells	NULL
.	NULL

Peptides	NULL
.	NULL

The	NULL
EBV	NULL
epitope	NULL
peptides	NULL
used	NULL
in	NULL
this	NULL
work	NULL
are	NULL
listed	NULL
in	NULL
Table	NULL
1	NULL
,	NULL
which	NULL
gives	NULL
their	NULL
EBV	NULL
antigen	NULL
location	NULL
,	NULL
amino	NULL
acid	NULL
sequence	NULL
,	NULL
and	NULL
human	NULL
lymphocyte	NULL
antigen	NULL
(	NULL
HLA	NULL
)	NULL
class	NULL
I	NULL
restriction	NULL
element	NULL
.	NULL

All	NULL
peptides	NULL
were	NULL
synthesized	NULL
by	NULL
9-fluorenylmethoxycarbonyl	NULL
chemistry	NULL
(	NULL
Alta	NULL
Bioscience	NULL
,	NULL
University	NULL
of	NULL
Birmingham	NULL
,	NULL
Birmingham	NULL
,	NULL
United	NULL
Kingdom	NULL
)	NULL
dissolved	NULL
in	NULL
dimethylsulfoxide	NULL
(	NULL
DMSO	NULL
)	NULL
,	NULL
and	NULL
their	NULL
concentrations	NULL
were	NULL
determined	NULL
by	NULL
biuret	NULL
assay	NULL
.	NULL

Peptides	NULL
were	NULL
used	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
50	NULL
g/m	NULL
!	NULL

for	NULL
loading	NULL
onto	NULL
DC	NULL
stimulators	NULL
and	NULL
at	NULL
5	NULL
pg/ml	NULL
for	NULL
presensitization	NULL
of	NULL
LCL	NULL
and	NULL
PHA	NULL
blast	NULL
target	NULL
cells	NULL
.	NULL

T-cell	NULL
stimulation	NULL
protocols	NULL
.	NULL

Donors	NULL
used	NULL
in	NULL
these	NULL
experiments	NULL
were	NULL
healthy	NULL
adults	NULL
of	NULL
known	NULL
HLA	NULL
type	NULL
and	NULL
of	NULL
known	NULL
EBV	NULL
antibody	NULL
status	NULL
as	NULL
determined	NULL
by	NULL
the	NULL
standard	NULL
immunofluorescence	NULL
assay	NULL
for	NULL
antiviral	NULL
capsid	NULL
antigen	NULL
reactivity	NULL
(	NULL
37	NULL
)	NULL
.	NULL

DC	NULL
stimulators	NULL
were	NULL
first	NULL
preexposed	NULL
for	NULL
2	NULL
h	NULL
at	NULL
37°C	NULL
to	NULL
peptides	NULL
in	NULL
serum-free	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
human	NULL
B2-microglobulin	NULL
at	NULL
3	NULL
pg/ml	NULL
and	NULL
then	NULL
washed	NULL
and	NULL
seeded	NULL
at	NULL
10°	NULL
cells/2-ml	NULL
well	NULL
in	NULL
RPMI-10	NULL
%	NULL
FCS	NULL
supplemented	NULL
with	NULL
recombinant	NULL
IL-7	NULL
(	NULL
r	NULL
[	NULL
L-7	NULL
)	NULL
at	NULL
5	NULL
ng/ml	NULL
.	NULL

Responder	NULL
PBMCs	NULL
were	NULL
added	NULL
at	NULL
2	NULL
X	NULL
10®/well	NULL
to	NULL
give	NULL
a	NULL
responder/stimulator	NULL
ratio	NULL
of	NULL
20:1	NULL
.	NULL

The	NULL
cultures	NULL
were	NULL
restimulated	NULL
on	NULL
days	NULL
14	NULL
and	NULL
21	NULL
with	NULL
autologous	NULL
peptide-loaded	NULL
cells	NULL
(	NULL
DCs	NULL
or	NULL
freshly	NULL
prepared	NULL
adherent	NULL
monocytes	NULL
)	NULL
now	NULL
in	NULL
RPMI-10	NULL
%	NULL
FCS	NULL
supplemented	NULL
with	NULL
rIL2	NULL
at	NULL
20	NULL
U/ml	NULL
.	NULL

The	NULL
cultures	NULL
were	NULL
expanded	NULL
into	NULL
additional	NULL
wells	NULL
on	NULL
day	NULL
14	NULL
,	NULL
if	NULL
necessary	NULL
,	NULL
and	NULL
on	NULL
day	NULL
21	NULL
.	NULL

Stimulation	NULL
with	NULL
peptide	NULL
alone	NULL
followed	NULL
a	NULL
protocol	NULL
based	NULL
on	NULL
that	NULL
of	NULL
Plebanski	NULL
et	NULL
al	NULL
.	NULL

(	NULL
36	NULL
)	NULL
which	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
able	NULL
to	NULL
reactivate	NULL
memory	NULL
CTLs	NULL
against	NULL
immunodominant	NULL
EBV	NULL
latent	NULL
cycle	NULL
epitopes	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
peptide	NULL
was	NULL
added	NULL
to	NULL
PBMC	NULL
cultures	NULL
(	NULL
2	NULL
X	NULL
10°	NULL
cells/2-ml	NULL
well	NULL
)	NULL
at	NULL
50	NULL
pg/ml	NULL
,	NULL
and	NULL
the	NULL
cells	NULL
were	NULL
then	NULL
maintained	NULL
in	NULL
RPMI-10	NULL
%	NULL
FCS	NULL
supplemented	NULL
with	NULL
rIL-7	NULL
at	NULL
20	NULL
ng/ml	NULL
from	NULL
day	NULL
0	NULL
and	NULL
with	NULL
rIL-2	NULL
at	NULL
20	NULL
U/ml	NULL
from	NULL
day	NULL
3	NULL
.	NULL

Stimulation	NULL
with	NULL
LCL	NULL
followed	NULL
the	NULL
standard	NULL
protocol	NULL
(	NULL
33	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
PBMCs	NULL
were	NULL
cocultured	NULL
with	NULL
y-irradiated	NULL
autologous	NULL
LCL	NULL
cells	NULL
in	NULL
2-ml	NULL
wells	NULL
in	NULL
RPMI-10	NULL
%	NULL
FCS	NULL
to	NULL
give	NULL
a	NULL
responder/stimulator	NULL
ratio	NULL
of	NULL
20:1	NULL
,	NULL
followed	NULL
by	NULL
restimulations	NULL
on	NULL
days	NULL
14	NULL
and	NULL
21	NULL
in	NULL
medium	NULL
supplemented	NULL
with	NULL
rIL-2	NULL
at	NULL
20	NULL
U/ml	NULL
.	NULL

Cytotoxicity	NULL
assays	NULL
.	NULL

Polyclonal	NULL
T-cell	NULL
populations	NULL
produced	NULL
by	NULL
the	NULL
above	NULL
stimulation	NULL
protocols	NULL
were	NULL
harvested	NULL
in	NULL
parallel	NULL
and	NULL
used	NULL
as	NULL
effectors	NULL
in	NULL
standard	NULL
5-h	NULL
chromium	NULL
release	NULL
assays	NULL
at	NULL
known	NULL
effector/target	NULL
ratios	NULL
.	NULL

Autologous	NULL
PHA	NULL
blasts	NULL
and	NULL
LCL	NULL
cells	NULL
were	NULL
used	NULL
as	NULL
targets	NULL
following	NULL
a	NULL
2-h	NULL
exposure	NULL
to	NULL
epitope	NULL
peptides	NULL
(	NULL
or	NULL
DMSO	NULL
solvent	NULL
as	NULL
a	NULL
control	NULL
)	NULL
and	NULL
extensive	NULL
washing	NULL
.	NULL

In	NULL
some	NULL
cases	NULL
the	NULL
LCL	NULL
targets	NULL
were	NULL
also	NULL
tested	NULL
after	NULL
overnight	NULL
infection	NULL
with	NULL
recombinant	NULL
vaccinia	NULL
viruses	NULL
encoding	NULL
individual	NULL
EBV	NULL
proteins	NULL
;	NULL
the	NULL
control	NULL
recombinant	NULL
vTK-	NULL
and	NULL
the	NULL
recombinants	NULL
expressing	NULL
EBNA3B	NULL
,	NULL
EBNA3C	NULL
,	NULL
LMP2	NULL
,	NULL
BMLF1	NULL
,	NULL
and	NULL
BMRF1	NULL
have	NULL
been	NULL
described	NULL
,	NULL
as	NULL
has	NULL
their	NULL
use	NULL
in	NULL
cytotoxicity	NULL
assays	NULL
(	NULL
33	NULL
,	NULL
49	NULL
)	NULL
.	NULL

RESULTS	NULL
Pilot	NULL
experiments	NULL
with	NULL
immunodominant	NULL
latent	NULL
cycle	NULL
epitopes	NULL
.	NULL

Throughout	NULL
this	NULL
study	NULL
DC	NULL
preparations	NULL
were	NULL
generated	NULL
from	NULL
PBMCs	NULL
by	NULL
7-day	NULL
culture	NULL
in	NULL
IL-4	NULL
and	NULL
GM-CSF	NULL
followed	NULL
by	NULL
a	NULL
2-day	NULL
maturation	NULL
step	NULL
in	NULL
macrophage-conditioned	NULL
me-dium	NULL
.	NULL

These	NULL
preparations	NULL
were	NULL
monitored	NULL
by	NULL
immunofluorescence	NULL
staining	NULL
and	NULL
contained	NULL
>	NULL
50	NULL
%	NULL
cells	NULL
with	NULL
surface	NULL
expression	NULL
of	NULL
the	NULL
mature	NULL
DC	NULL
marker	NULL
CD83	NULL
(	NULL
59	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
CD54	NULL
,	NULL
CD80	NULL
,	NULL
and	NULL
CD86	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
the	NULL
first	NULL
series	NULL
of	NULL
experiments	NULL
we	NULL
aimed	NULL
to	NULL
assess	NULL
the	NULL
in	NULL
vitro	NULL
stimulatory	NULL
capacity	NULL
of	NULL
peptide-loaded	NULL
DCs	NULL
by	NULL
using	NULL
defined	NULL
epitope	NULL
peptides	NULL
from	NULL
the	NULL
immunodominant	NULL
EBNA3A	NULL
,	NULL
-3B	NULL
,	NULL
and	NULL
-3C	NULL
subset	NULL
of	NULL
latent	NULL
cycle	NULL
proteins	NULL
.	NULL

Peripheral	NULL
blood	NULL
responder	NULL
cells	NULL
from	NULL
selected	NULL
336	NULL
REDCHENKO	NULL
AND	NULL
RICKINSON	NULL
A	NULL
LY	NULL
(	NULL
+ve	NULL
)	NULL
{	NULL
t	NULL
RRLIDC	NULL
QAK/DC	NULL
40	NULL
40	NULL
0	NULL
0	NULL
RRA/DC	NULL
FLR/DC	NULL
40	NULL
40	NULL
0	NULL
o	NULL
;	NULL
LCL	NULL
LCL	NULL
40	NULL
40	NULL
0	NULL
E	NULL
]	NULL
E	NULL
5	NULL
o	NULL
z	NULL
m	NULL
bo	NULL
ibs	NULL
?	NULL

L______J	NULL
L222	NULL
PHA	NULL
targets	NULL
-	NULL
LCL	NULL
targets	NULL
+	NULL
peptide	NULL
+	NULL
peptide	NULL
J.	NULL
Virou	NULL
.	NULL

AR	NULL
(	NULL
+ve	NULL
)	NULL
so	NULL
1	NULL
!	NULL

1	NULL
80	NULL
40	NULL
Mor	NULL
<	NULL
a	NULL
§	NULL
4	NULL
O	NULL
t	NULL
¥	NULL
%	NULL
F	NULL
t	NULL
x	NULL
4	NULL
S	NULL
&	NULL
<	NULL
&	NULL
»	NULL
l	NULL
8	NULL
35	NULL
E	NULL
5	NULL
3k	NULL
5	NULL
3	NULL
E	NULL
L	NULL
1	NULL
l	NULL
1	NULL
L	NULL
I	NULL
d	NULL
I	NULL
PHA	NULL
targets	NULL
-	NULL
LCL	NULL
targets	NULL
PHA	NULL
targets	NULL
LCL	NULL
targets	NULL
+	NULL
peptide	NULL
+	NULL
peptide	NULL
+	NULL
peptide	NULL
+	NULL
peptide	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Cytotoxic	NULL
activities	NULL
of	NULL
polyclonal	NULL
effector	NULL
T	NULL
cells	NULL
induced	NULL
by	NULL
peptide-loaded	NULL
autologous	NULL
DC	NULL
stimulation	NULL
(	NULL
peptide/DC	NULL
)	NULL
or	NULL
by	NULL
autologous	NULL
LCL	NULL
stimulation	NULL
(	NULL
LCL	NULL
)	NULL
.	NULL

(	NULL
A	NULL
)	NULL
EBV-immune	NULL
donor	NULL
LY	NULL
(	NULL
HLA-A1	NULL
,	NULL
A24.02	NULL
,	NULL
B27.02	NULL
,	NULL
B35.02	NULL
)	NULL
responses	NULL
to	NULL
the	NULL
immunodominant	NULL
B27.02-restricted	NULL
latent-cycle	NULL
epitopes	NULL
RRI	NULL
and	NULL
RRA	NULL
versus	NULL
the	NULL
response	NULL
to	NULL
B95.8	NULL
virus-transformed	NULL
LCL	NULL
.	NULL

(	NULL
B	NULL
)	NULL
EBV-immune	NULL
donor	NULL
AR	NULL
(	NULL
HLA-A1	NULL
,	NULL
B8	NULL
,	NULL
B57	NULL
)	NULL
and	NULL
nonimmune	NULL
donor	NULL
LS	NULL
(	NULL
HLA-A1	NULL
,	NULL
B8	NULL
)	NULL
responses	NULL
to	NULL
the	NULL
immunodominant	NULL
B	NULL
&	NULL
-restricted	NULL
latent	NULL
cycle	NULL
epitopes	NULL
QAK	NULL
and	NULL
FLR	NULL
versus	NULL
the	NULL
response	NULL
to	NULL
BL74	NULL
virus-transformed	NULL
LCL	NULL
.	NULL

Effector	NULL
T	NULL
cells	NULL
were	NULL
tested	NULL
at	NULL
an	NULL
effector/target	NULL
(	NULL
E/T	NULL
)	NULL
ratio	NULL
of	NULL
10:1	NULL
on	NULL
autologous	NULL
PHA	NULL
blast	NULL
targets	NULL
and	NULL
on	NULL
autologous	NULL
B95.8	NULL
virus-transformed	NULL
LCL	NULL
targets	NULL
either	NULL
untreated	NULL
(	NULL
Cont	NULL
)	NULL
or	NULL
following	NULL
target	NULL
cell	NULL
exposure	NULL
to	NULL
5	NULL
pg	NULL
of	NULL
peptides	NULL
per	NULL
ml	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
percent	NULL
specific	NULL
cytotoxicity	NULL
observed	NULL
in	NULL
a	NULL
5-h	NULL
chromium	NULL
release	NULL
assay	NULL
.	NULL

donors	NULL
were	NULL
challenged	NULL
in	NULL
vitro	NULL
with	NULL
peptide-loaded	NULL
autologous	NULL
DC	NULL
stimulators	NULL
,	NULL
and	NULL
the	NULL
resulting	NULL
effector	NULL
population	NULL
was	NULL
assayed	NULL
against	NULL
autologous	NULL
targets	NULL
(	NULL
PHA	NULL
blast	NULL
and	NULL
LCL	NULL
)	NULL
with	NULL
or	NULL
without	NULL
their	NULL
preexposure	NULL
to	NULL
the	NULL
relevant	NULL
peptide	NULL
.	NULL

Preliminary	NULL
experiments	NULL
showed	NULL
that	NULL
peptide-specific	NULL
reactivities	NULL
were	NULL
detectable	NULL
at	NULL
low	NULL
levels	NULL
in	NULL
DC-stimulated	NULL
cultures	NULL
on	NULL
day	NULL
14	NULL
but	NULL
against	NULL
a	NULL
background	NULL
of	NULL
nonspecific	NULL
lysis	NULL
;	NULL
however	NULL
,	NULL
two	NULL
further	NULL
stimulations	NULL
on	NULL
days	NULL
14	NULL
and	NULL
21	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IL-2	NULL
selectively	NULL
amplified	NULL
the	NULL
peptide-specific	NULL
CTL	NULL
population	NULL
.	NULL

Data	NULL
in	NULL
the	NULL
present	NULL
study	NULL
are	NULL
from	NULL
such	NULL
restimulated	NULL
popula-tions	NULL
;	NULL
in	NULL
each	NULL
experiment	NULL
,	NULL
parallel	NULL
effectors	NULL
were	NULL
generated	NULL
from	NULL
the	NULL
same	NULL
donor	NULL
by	NULL
conventional	NULL
LCL	NULL
stimulation	NULL
on	NULL
day	NULL
0	NULL
followed	NULL
by	NULL
LCL	NULL
restimulation	NULL
and	NULL
IL-2	NULL
addition	NULL
on	NULL
days	NULL
14	NULL
and	NULL
21	NULL
.	NULL

Figure	NULL
1A	NULL
presents	NULL
typical	NULL
results	NULL
from	NULL
an	NULL
HLA-B27.02-positive	NULL
EBV-immune	NULL
donor	NULL
,	NULL
LY	NULL
,	NULL
already	NULL
known	NULL
to	NULL
possess	NULL
memory	NULL
CTLs	NULL
to	NULL
two	NULL
immunodominant	NULL
B27.02-restricted	NULL
latent	NULL
cycle	NULL
epitopes	NULL
,	NULL
the	NULL
EBNA3C-derived	NULL
epitope	NULL
RRIYDLIEL	NULL
(	NULL
designated	NULL
RRI	NULL
)	NULL
and	NULL
the	NULL
EBNA3B-derived	NULL
epitope	NULL
RRARSL	NULL
SAERY	NULL
(	NULL
designated	NULL
RRA	NULL
)	NULL
(	NULL
9	NULL
,	NULL
10	NULL
)	NULL
.	NULL

Conventional	NULL
LCL	NULL
stimulation	NULL
generated	NULL
a	NULL
polyclonal	NULL
CTL	NULL
population	NULL
containing	NULL
both	NULL
RRl-specific	NULL
and	NULL
RRA-specific	NULL
effectors	NULL
;	NULL
these	NULL
could	NULL
be	NULL
detected	NULL
both	NULL
by	NULL
using	NULL
peptide-loaded	NULL
PHA	NULL
blast	NULL
or	NULL
peptide-loaded	NULL
LCL	NULL
targets	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
,	NULL
LCL	NULL
data	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
effector	NULL
CTLs	NULL
generated	NULL
by	NULL
peptide-loaded	NULL
DC	NULL
stimulators	NULL
were	NULL
preferentially	NULL
directed	NULL
against	NULL
the	NULL
stimulator	NULL
peptide	NULL
,	NULL
either	NULL
RRI	NULL
or	NULL
RRA	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
,	NULL
RRI/DC	NULL
and	NULL
RRA/DC	NULL
data	NULL
)	NULL
.	NULL

Note	NULL
that	NULL
RRI-stimulated	NULL
effectors	NULL
showed	NULL
higher	NULL
levels	NULL
of	NULL
lysis	NULL
of	NULL
the	NULL
untreated	NULL
autologous	NULL
LCL	NULL
target	NULL
than	NULL
did	NULL
RRA-stimulated	NULL
effectors	NULL
,	NULL
though	NULL
in	NULL
both	NULL
cases	NULL
levels	NULL
of	NULL
killing	NULL
were	NULL
enhanced	NULL
by	NULL
exogenous	NULL
peptide	NULL
loading	NULL
.	NULL

These	NULL
differences	NULL
in	NULL
lysis	NULL
of	NULL
the	NULL
naturally	NULL
infected	NULL
LCL	NULL
targets	NULL
resemble	NULL
those	NULL
already	NULL
noted	NULL
with	NULL
epitope-specific	NULL
clones	NULL
derived	NULL
from	NULL
donor	NULL
LY	NULL
by	NULL
conventional	NULL
LCL	NULL
stimulation	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Figure	NULL
1B	NULL
(	NULL
left	NULL
)	NULL
presents	NULL
parallel	NULL
data	NULL
from	NULL
an	NULL
HLA-B8-positive	NULL
EBV-immune	NULL
donor	NULL
AR	NULL
known	NULL
to	NULL
possess	NULL
memory	NULL
CTLs	NULL
to	NULL
two	NULL
B	NULL
&	NULL
8-restricted	NULL
latent	NULL
cycle	NULL
epitopes	NULL
in	NULL
EBNA3A	NULL
:	NULL
QAKWRLQTL	NULL
(	NULL
designated	NULL
QAK	NULL
)	NULL
and	NULL
FLRGRAYGL	NULL
(	NULL
designated	NULL
FLR	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
stimulation	NULL
with	NULL
autologous	NULL
LCL	NULL
(	NULL
carrying	NULL
a	NULL
viral	NULL
strain	NULL
BL74	NULL
encoding	NULL
both	NULL
epitopes	NULL
[	NULL
2	NULL
]	NULL
)	NULL
reactivated	NULL
both	NULL
components	NULL
of	NULL
virus-specific	NULL
memory	NULL
.	NULL

Strong	NULL
reactivation	NULL
was	NULL
also	NULL
induced	NULL
by	NULL
using	NULL
peptide-loaded	NULL
DCs	NULL
but	NULL
was	NULL
selective	NULL
for	NULL
the	NULL
specific	NULL
epitope	NULL
peptide	NULL
used	NULL
.	NULL

Note	NULL
that	NULL
QAK-stimulated	NULL
effectors	NULL
(	NULL
QAK/DC	NULL
)	NULL
did	NULL
recognize	NULL
naturally	NULL
infected	NULL
LCL	NULL
target	NULL
cells	NULL
even	NULL
without	NULL
peptide	NULL
loading	NULL
,	NULL
whereas	NULL
the	NULL
FLR-stimulated	NULL
effectors	NULL
(	NULL
FLR/DC	NULL
)	NULL
did	NULL
not	NULL
;	NULL
this	NULL
reflects	NULL
the	NULL
fact	NULL
that	NULL
in	NULL
these	NULL
particular	NULL
assays	NULL
the	NULL
autologous	NULL
LCL	NULL
target	NULL
carried	NULL
a	NULL
viral	NULL
strain	NULL
(	NULL
B95.8	NULL
)	NULL
with	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
FLR	NULL
epitope	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Similar	NULL
data	NULL
were	NULL
obtained	NULL
from	NULL
a	NULL
second	NULL
voL	NULL
.	NULL

73	NULL
,	NULL
1999	NULL
HLA-B8-positive	NULL
EBV-immune	NULL
donor	NULL
,	NULL
MR	NULL
,	NULL
who	NULL
also	NULL
mounted	NULL
strong	NULL
epitope-specific	NULL
responses	NULL
to	NULL
QAK-	NULL
and	NULL
to	NULL
FLR-loaded	NULL
DCs	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Using	NULL
the	NULL
same	NULL
protocol	NULL
,	NULL
we	NULL
then	NULL
studied	NULL
two	NULL
HLA-B8-positive	NULL
donors	NULL
,	NULL
LS	NULL
and	NULL
IA	NULL
,	NULL
who	NULL
were	NULL
nonimmune	NULL
as	NULL
reflected	NULL
by	NULL
EBV	NULL
antibody	NULL
negativity	NULL
in	NULL
sero-logical	NULL
assays	NULL
.	NULL

Both	NULL
individuals	NULL
were	NULL
tested	NULL
on	NULL
two	NULL
successive	NULL
occasions	NULL
by	NULL
using	NULL
peptide-loaded	NULL
DC	NULL
stimulators	NULL
and	NULL
autologous	NULL
LCL	NULL
stimulators	NULL
but	NULL
gave	NULL
no	NULL
evidence	NULL
of	NULL
any	NULL
epitope-specific	NULL
response	NULL
.	NULL

Figure	NULL
1B	NULL
(	NULL
right	NULL
)	NULL
shows	NULL
the	NULL
data	NULL
from	NULL
one	NULL
such	NULL
experiment	NULL
with	NULL
donor	NULL
LS	NULL
.	NULL

Although	NULL
all	NULL
three	NULL
types	NULL
of	NULL
coculture	NULL
generated	NULL
T-cell	NULL
proliferation	NULL
which	NULL
was	NULL
sustained	NULL
in	NULL
rIL-2	NULL
,	NULL
no	NULL
cytotoxicity	NULL
was	NULL
detectable	NULL
against	NULL
either	NULL
autologous	NULL
PHA	NULL
blast	NULL
or	NULL
LCL	NULL
targets	NULL
with	NULL
or	NULL
without	NULL
peptide	NULL
loading	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
from	NULL
a	NULL
second	NULL
EBV	NULL
nonimmune	NULL
donor	NULL
,	NULL
IA	NULL
,	NULL
with	NULL
QAK-loaded	NULL
or	NULL
FLR-loaded	NULL
DC	NULL
stimulators	NULL
;	NULL
in	NULL
this	NULL
case	NULL
LCL	NULL
stimulations	NULL
produced	NULL
broad-ranging	NULL
cytotoxicity	NULL
detectable	NULL
on	NULL
various	NULL
target	NULL
lines	NULL
but	NULL
no	NULL
EBV	NULL
epitope-specific	NULL
killing	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
subsequent	NULL
experiments	NULL
we	NULL
tested	NULL
the	NULL
above	NULL
DC-based	NULL
stimulation	NULL
protocol	NULL
against	NULL
an	NULL
alternative	NULL
published	NULL
method	NULL
for	NULL
the	NULL
in	NULL
vitro	NULL
reactivation	NULL
of	NULL
virus-specific	NULL
CTL	NULL
memory	NULL
(	NULL
23	NULL
)	NULL
;	NULL
this	NULL
method	NULL
involves	NULL
the	NULL
addition	NULL
of	NULL
peptide	NULL
to	NULL
mononuclear	NULL
cell	NULL
cultures	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IL-7	NULL
,	NULL
a	NULL
cytokine	NULL
found	NULL
to	NULL
improve	NULL
peptide-induced	NULL
responses	NULL
in	NULL
vitro	NULL
(	NULL
36	NULL
)	NULL
,	NULL
and	NULL
expansion	NULL
of	NULL
reactive	NULL
cells	NULL
by	NULL
IL-2	NULL
supplementation	NULL
from	NULL
day	NULL
3	NULL
onwards	NULL
.	NULL

In	NULL
assays	NULL
on	NULL
a	NULL
range	NULL
of	NULL
EBV-immune	NULL
donors	NULL
,	NULL
we	NULL
found	NULL
that	NULL
the	NULL
DC-based	NULL
protocol	NULL
induced	NULL
stronger	NULL
and	NULL
more	NULL
consistent	NULL
epitope-specific	NULL
responses	NULL
and	NULL
lower	NULL
background	NULL
reactivity	NULL
.	NULL

This	NULL
is	NULL
illustrated	NULL
by	NULL
the	NULL
representative	NULL
results	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
obtained	NULL
from	NULL
an	NULL
HLA-A11	NULL
,	NULL
B8-positive	NULL
donor	NULL
,	NULL
CMe	NULL
,	NULL
known	NULL
to	NULL
possess	NULL
memory	NULL
CTLs	NULL
to	NULL
two	NULL
All-restricted	NULL
epitopes	NULL
in	NULL
EBNA3B	NULL
,	NULL
IVTDFSVIK	NULL
(	NULL
designated	NULL
IVT	NULL
)	NULL
and	NULL
AVFDRKSDAK	NULL
(	NULL
designated	NULL
AVF	NULL
)	NULL
,	NULL
and	NULL
to	NULL
the	NULL
B	NULL
&	NULL
8-restricted	NULL
epitope	NULL
QAK	NULL
.	NULL

The	NULL
non-DC	NULL
stimulation	NULL
protocol	NULL
produced	NULL
detectable	NULL
responses	NULL
to	NULL
the	NULL
IVT	NULL
and	NULL
QAK	NULL
epitopes	NULL
but	NULL
not	NULL
to	NULL
AVF	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
left	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
all	NULL
three	NULL
peptides	NULL
presented	NULL
on	NULL
autologous	NULL
DCs	NULL
induced	NULL
polyclonal	NULL
effector	NULL
populations	NULL
with	NULL
a	NULL
strong	NULL
epitope-specific	NULL
component	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
right	NULL
)	NULL
.	NULL

The	NULL
latter	NULL
was	NULL
detectable	NULL
on	NULL
peptide-loaded	NULL
PHA	NULL
blast	NULL
targets	NULL
and	NULL
,	NULL
as	NULL
incremental	NULL
lysis	NULL
,	NULL
on	NULL
LCL	NULL
targets	NULL
either	NULL
preloaded	NULL
with	NULL
the	NULL
relevant	NULL
peptide	NULL
or	NULL
expressing	NULL
increased	NULL
levels	NULL
of	NULL
the	NULL
relevant	NULL
target	NULL
antigen	NULL
(	NULL
EBNA3A	NULL
or	NULL
EBNA3B	NULL
)	NULL
from	NULL
a	NULL
recombinant	NULL
vaccinia	NULL
virus	NULL
vector	NULL
.	NULL

Responses	NULL
to	NULL
defined	NULL
lytic	NULL
cycle	NULL
epitopes	NULL
.	NULL

Following	NULL
the	NULL
identification	NULL
of	NULL
a	NULL
number	NULL
of	NULL
EBV	NULL
lytic	NULL
antigen-derived	NULL
epitopes	NULL
recognized	NULL
by	NULL
components	NULL
of	NULL
the	NULL
primary	NULL
virus-induced	NULL
CTL	NULL
response	NULL
in	NULL
IM	NULL
patients	NULL
(	NULL
49	NULL
)	NULL
,	NULL
here	NULL
we	NULL
used	NULL
stimulation	NULL
with	NULL
peptide-loaded	NULL
DCs	NULL
to	NULL
probe	NULL
the	NULL
T-cell	NULL
pool	NULL
of	NULL
long-term	NULL
virus	NULL
carriers	NULL
for	NULL
evidence	NULL
of	NULL
such	NULL
reactivities	NULL
in	NULL
CTL	NULL
memory	NULL
.	NULL

Two	NULL
such	NULL
epitopes	NULL
,	NULL
restricted	NULL
through	NULL
the	NULL
HLA	NULL
A2.01	NULL
allele	NULL
,	NULL
are	NULL
the	NULL
peptides	NULL
GLCTLVAML	NULL
(	NULL
designated	NULL
GLC	NULL
)	NULL
and	NULL
TLDY	NULL
KPLSV	NULL
(	NULL
designated	NULL
TLD	NULL
)	NULL
,	NULL
derived	NULL
from	NULL
the	NULL
EBV	NULL
early	NULL
lytic	NULL
cycle	NULL
antigens	NULL
BMLF1	NULL
and	NULL
BMRF1	NULL
,	NULL
respectively	NULL
.	NULL

We	NULL
first	NULL
screened	NULL
two	NULL
HLA-A2.01-positive	NULL
EBV	NULL
carriers	NULL
,	NULL
JS	NULL
and	NULL
SL	NULL
,	NULL
for	NULL
CTL	NULL
reactivity	NULL
to	NULL
these	NULL
epitopes	NULL
and	NULL
in	NULL
both	NULL
individuals	NULL
detected	NULL
specific	NULL
responses	NULL
to	NULL
both	NULL
epitopes	NULL
in	NULL
at	NULL
least	NULL
two	NULL
independent	NULL
in	NULL
vitro	NULL
reactivations	NULL
.	NULL

Representative	NULL
results	NULL
from	NULL
one	NULL
experiment	NULL
with	NULL
donor	NULL
JS	NULL
are	NULL
illustrated	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Stimulation	NULL
with	NULL
GLC-loaded	NULL
or	NULL
with	NULL
TLD-loaded	NULL
DCs	NULL
produced	NULL
effector	NULL
populations	NULL
which	NULL
specifically	NULL
recognized	NULL
PHA	NULL
blasts	NULL
preloaded	NULL
with	NULL
the	NULL
relevant	NULL
peptide	NULL
.	NULL

Note	NULL
here	NULL
that	NULL
baseline	NULL
levels	NULL
of	NULL
LCL	NULL
lysis	NULL
are	NULL
low	NULL
because	NULL
LCL	NULL
populations	NULL
contain	NULL
very	NULL
few	NULL
lytically	NULL
infected	NULL
cells	NULL
;	NULL
however	NULL
,	NULL
LCLs	NULL
could	NULL
be	NULL
sensitized	NULL
to	NULL
lysis	NULL
either	NULL
by	NULL
exogenous	NULL
peptide	NULL
or	NULL
by	NULL
infection	NULL
with	NULL
a	NULL
recombinant	NULL
vaccinia	NULL
virus	NULL
expressing	NULL
the	NULL
relevant	NULL
lytic	NULL
cycle	NULL
protein	NULL
:	NULL
BMLF1	NULL
in	NULL
the	NULL
case	NULL
of	NULL
GLC-specific	NULL
T	NULL
cells	NULL
and	NULL
DENDRITIC	NULL
CELL	NULL
STIMULATION	NULL
OF	NULL
EBV-SPECIFIC	NULL
T	NULL
CELLS	NULL
-	NULL
337	NULL
CMe	NULL
(	NULL
+ve	NULL
)	NULL
IVT	NULL
IVTDC	NULL
40	NULL
40	NULL
20	NULL
AVF	NULL
AVEDC	NULL
40	NULL
40	NULL
20	NULL
QAK	NULL
QAKDC	NULL
40	NULL
40	NULL
20	NULL
PH	NULL
targets	NULL
+	NULL
peptide	NULL
LCL	NULL
targets	NULL
LCL	NULL
targets	NULL
+	NULL
peptide	NULL
+	NULL
vace	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Cytotoxic	NULL
activities	NULL
of	NULL
polyclonal	NULL
effector	NULL
T	NULL
cells	NULL
induced	NULL
by	NULL
stimulation	NULL
with	NULL
peptide	NULL
alone	NULL
or	NULL
with	NULL
peptide-loaded	NULL
autologous	NULL
DCs	NULL
(	NULL
peptide/DC	NULL
)	NULL
.	NULL

Responses	NULL
are	NULL
shown	NULL
from	NULL
EBV-immune	NULL
donor	NULL
CMe	NULL
(	NULL
HLA-A2.01	NULL
,	NULL
A11.01	NULL
,	NULL
B8	NULL
,	NULL
B44	NULL
)	NULL
to	NULL
the	NULL
immunodominant	NULL
A1l-restricted	NULL
latent	NULL
cycle	NULL
epitopes	NULL
IVT	NULL
and	NULL
AVF	NULL
(	NULL
both	NULL
from	NULL
EBNA3B	NULL
)	NULL
and	NULL
to	NULL
the	NULL
immunodominant	NULL
B8-restricted	NULL
epitope	NULL
QAK	NULL
(	NULL
from	NULL
EBNA3A	NULL
)	NULL
.	NULL

Effector	NULL
T	NULL
cells	NULL
were	NULL
tested	NULL
(	NULL
E/T	NULL
,	NULL
10:1	NULL
)	NULL
on	NULL
autologous	NULL
PHA	NULL
blast	NULL
and	NULL
LCL	NULL
targets	NULL
either	NULL
untreated	NULL
or	NULL
peptide-loaded	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
or	NULL
on	NULL
LCL	NULL
targets	NULL
infected	NULL
with	NULL
recombinant	NULL
vaccinia	NULL
viruses	NULL
vTK	NULL
~	NULL
,	NULL
vE3B	NULL
,	NULL
(	NULL
expressing	NULL
EBNA3B	NULL
)	NULL
,	NULL
and	NULL
vE3A	NULL
(	NULL
expressing	NULL
EBNA3A	NULL
)	NULL
.	NULL

BMRF1	NULL
in	NULL
the	NULL
case	NULL
of	NULL
TLD-specific	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
GLC/DC	NULL
and	NULL
TLD/DC	NULL
data	NULL
)	NULL
.	NULL

In	NULL
the	NULL
same	NULL
experiment	NULL
,	NULL
LCL	NULL
stimulation	NULL
produced	NULL
latent	NULL
antigen-specific	NULL
effectors	NULL
capable	NULL
of	NULL
recognizing	NULL
the	NULL
LCL	NULL
target	NULL
but	NULL
did	NULL
not	NULL
induce	NULL
any	NULL
detectable	NULL
response	NULL
to	NULL
the	NULL
lytic	NULL
cycle	NULL
epitopes	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
LCL	NULL
data	NULL
)	NULL
.	NULL

In	NULL
a	NULL
similar	NULL
way	NULL
it	NULL
was	NULL
possible	NULL
to	NULL
detect	NULL
memory	NULL
CTL	NULL
responses	NULL
to	NULL
other	NULL
defined	NULL
lytic	NULL
cycle	NULL
epitopes	NULL
from	NULL
EBV-immune	NULL
donors	NULL
with	NULL
relevant	NULL
HLA	NULL
types	NULL
.	NULL

For	NULL
instance	NULL
,	NULL
responses	NULL
to	NULL
the	NULL
BS8-restricted	NULL
epitope	NULL
RAKFKQLL	NULL
(	NULL
designated	NULL
RAK	NULL
)	NULL
from	NULL
the	NULL
immediate-early	NULL
lytic	NULL
cycle	NULL
protein	NULL
BZLF1	NULL
were	NULL
seen	NULL
in	NULL
all	NULL
three	NULL
B8-positive	NULL
individuals	NULL
tested	NULL
(	NULL
AR	NULL
,	NULL
MR	NULL
,	NULL
and	NULL
CMc	NULL
)	NULL
,	NULL
and	NULL
responses	NULL
to	NULL
the	NULL
B35.01-restricted	NULL
epitope	NULL
APENAYQAY	NULL
,	NULL
also	NULL
from	NULL
BZLF1	NULL
were	NULL
seen	NULL
in	NULL
the	NULL
B35.01-positive	NULL
virus	NULL
carrier	NULL
RT	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
strength	NULL
of	NULL
the	NULL
GLC-induced	NULL
and	NULL
RAK-induced	NULL
CTL	NULL
responses	NULL
in	NULL
the	NULL
above	NULL
experiments	NULL
led	NULL
us	NULL
to	NULL
reexamine	NULL
EBV-immune	NULL
versus	NULL
nonimmune	NULL
individuals	NULL
in	NULL
their	NULL
responses	NULL
to	NULL
DC	NULL
stimulation	NULL
with	NULL
these	NULL
particular	NULL
epitope	NULL
peptides	NULL
.	NULL

Figure	NULL
4	NULL
shows	NULL
representative	NULL
data	NULL
from	NULL
such	NULL
experiments	NULL
.	NULL

Both	NULL
of	NULL
the	NULL
HLA-A2.01-positive	NULL
EBV-immune	NULL
donors	NULL
,	NULL
DA	NULL
and	NULL
SL	NULL
,	NULL
generated	NULL
polyclonal	NULL
T-cell	NULL
populations	NULL
with	NULL
strong	NULL
epitope-specific	NULL
reactivity	NULL
following	NULL
stimulation	NULL
with	NULL
GLC-loaded	NULL
DCs	NULL
,	NULL
whereas	NULL
the	NULL
A2.01-positive	NULL
nonimmune	NULL
donors	NULL
CD	NULL
and	NULL
LD	NULL
gave	NULL
no	NULL
detectable	NULL
reactivity	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

A	NULL
similar	NULL
pattern	NULL
of	NULL
338	NULL
REDCHENKO	NULL
AND	NULL
RICKINSON	NULL
JS	NULL
(	NULL
+ve	NULL
)	NULL
GLCDC	NULL
40	NULL
TLD/DC	NULL
LCL	NULL
moors	NULL
F	NULL
a	NULL
#	NULL
A	NULL
;	NULL
biG	NULL
,	NULL
PHA	NULL
targets	NULL
-	NULL
LCL	NULL
targets	NULL
-	NULL
LCL	NULL
targets	NULL
+	NULL
peptide	NULL
+	NULL
peptide	NULL
+	NULL
vace	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Cytotoxic	NULL
activities	NULL
of	NULL
polyclonal	NULL
effector	NULL
T	NULL
cells	NULL
induced	NULL
by	NULL
peptide-loaded	NULL
autologous	NULL
DC	NULL
stimulation	NULL
(	NULL
peptide/DC	NULL
)	NULL
or	NULL
by	NULL
autologous	NULL
B95.8	NULL
virus-transformed	NULL
LCL	NULL
stimulation	NULL
(	NULL
LCL	NULL
)	NULL
.	NULL

Responses	NULL
are	NULL
shown	NULL
from	NULL
EBV-immune	NULL
donor	NULL
JS	NULL
(	NULL
HLA-A2.01	NULL
,	NULL
B27.05	NULL
,	NULL
B44	NULL
)	NULL
to	NULL
the	NULL
A2.01-restricted	NULL
lytic-cycle	NULL
epitopes	NULL
GLC	NULL
(	NULL
from	NULL
BMLF1	NULL
)	NULL
and	NULL
TLD	NULL
(	NULL
from	NULL
BMRF1	NULL
}	NULL
.	NULL

Effector	NULL
T	NULL
cells	NULL
were	NULL
tested	NULL
(	NULL
E/T	NULL
,	NULL
10:1	NULL
)	NULL
on	NULL
autologous	NULL
PHA	NULL
blast	NULL
and	NULL
LCL	NULL
targets	NULL
either	NULL
untreated	NULL
or	NULL
peptide-loaded	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
or	NULL
on	NULL
LCL	NULL
targets	NULL
infected	NULL
with	NULL
recombinant	NULL
vaccinia	NULL
viruses	NULL
vTK~	NULL
,	NULL
vBMLFI1	NULL
(	NULL
expressing	NULL
BMLF1	NULL
)	NULL
,	NULL
and	NULL
vBMRF1	NULL
(	NULL
expressing	NULL
BMRF1	NULL
}	NULL
.	NULL

results	NULL
were	NULL
obtained	NULL
by	NULL
using	NULL
the	NULL
B8-restricted	NULL
RAK	NULL
epitope	NULL
peptide	NULL
.	NULL

Strong	NULL
responses	NULL
were	NULL
detected	NULL
in	NULL
polyclonal	NULL
cultures	NULL
from	NULL
the	NULL
two	NULL
EBV-immune	NULL
donors	NULL
AR	NULL
and	NULL
MR	NULL
but	NULL
were	NULL
not	NULL
detectable	NULL
in	NULL
the	NULL
parallel	NULL
cultures	NULL
established	NULL
from	NULL
nonimmune	NULL
donors	NULL
IA	NULL
and	NULL
LS	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

Responses	NULL
to	NULL
epitopes	NULL
from	NULL
the	NULL
subdominant	NULL
latent	NULL
cycle	NULL
protein	NULL
LMP2	NULL
.	NULL

We	NULL
next	NULL
asked	NULL
whether	NULL
DC	NULL
stimulation	NULL
was	NULL
capable	NULL
of	NULL
accessing	NULL
low-frequency	NULL
components	NULL
of	NULL
CTL	NULL
mem-ory	NULL
,	NULL
in	NULL
particular	NULL
CTLs	NULL
specific	NULL
for	NULL
defined	NULL
epitopes	NULL
in	NULL
the	NULL
subdominant	NULL
latent	NULL
cycle	NULL
protein	NULL
LMP2	NULL
.	NULL

We	NULL
first	NULL
chose	NULL
two	NULL
EBV-immune	NULL
donors	NULL
whose	NULL
polyclonal	NULL
CTL	NULL
response	NULL
to	NULL
conventional	NULL
LCL	NULL
stimulation	NULL
is	NULL
known	NULL
to	NULL
contain	NULL
a	NULL
small	NULL
but	NULL
detectable	NULL
LMP2-specific	NULL
component	NULL
.	NULL

Donor	NULL
WT	NULL
(	NULL
A2.01-pos-itive	NULL
)	NULL
gives	NULL
an	NULL
unusually	NULL
weak	NULL
response	NULL
to	NULL
LCL	NULL
stimulation	NULL
,	NULL
the	NULL
only	NULL
detectable	NULL
EBV	NULL
latent	NULL
antigen-specific	NULL
reactivity	NULL
being	NULL
to	NULL
an	NULL
A2.01-restricted	NULL
epitope	NULL
LLWTLVVLL	NULL
(	NULL
designated	NULL
LLW	NULL
)	NULL
in	NULL
LMP2	NULL
.	NULL

This	NULL
is	NULL
illustrated	NULL
in	NULL
Fig	NULL
.	NULL

5A	NULL
(	NULL
LCL	NULL
data	NULL
)	NULL
,	NULL
where	NULL
LCL-stimulated	NULL
effectors	NULL
from	NULL
this	NULL
donor	NULL
not	NULL
only	NULL
failed	NULL
to	NULL
kill	NULL
the	NULL
LCL	NULL
but	NULL
also	NULL
contained	NULL
barely	NULL
detectable	NULL
reactivity	NULL
against	NULL
LLW	NULL
peptide-loaded	NULL
targets	NULL
and	NULL
no	NULL
detectable	NULL
reactivity	NULL
to	NULL
a	NULL
second	NULL
A2.01-restricted	NULL
epitope	NULL
within	NULL
LMP2	NULL
,	NULL
CLGGLLTMV	NULL
(	NULL
designated	NULL
CLG	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
vitro	NULL
stimulation	NULL
with	NULL
these	NULL
peptides	NULL
presented	NULL
on	NULL
DCs	NULL
was	NULL
able	NULL
to	NULL
selectively	NULL
induce	NULL
responses	NULL
both	NULL
to	NULL
LLW	NULL
and	NULL
to	NULL
CLG	NULL
;	NULL
these	NULL
effectors	NULL
recognized	NULL
peptide-loaded	NULL
targets	NULL
and	NULL
also	NULL
targets	NULL
endogenously	NULL
expressing	NULL
LMP2	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
LLW/DC	NULL
and	NULL
CLG/DC	NULL
data	NULL
)	NULL
.	NULL

In	NULL
a	NULL
second	NULL
donor	NULL
,	NULL
SL	NULL
(	NULL
A2.01	NULL
,	NULL
B40.01-positive	NULL
)	NULL
,	NULL
LCL	NULL
stimulation	NULL
gener-	NULL
J.	NULL
Virou	NULL
.	NULL

RAK/DC	NULL
[	NULL
--	NULL
-I	NULL
GLC/DC	NULL
DA	NULL
(	NULL
+ve	NULL
)	NULL
AR	NULL
(	NULL
+ve	NULL
)	NULL
40	NULL
40	NULL
SL	NULL
(	NULL
+ve	NULL
)	NULL
MR	NULL
(	NULL
+ve	NULL
)	NULL
40	NULL
~	NULL
40	NULL
CD	NULL
(	NULL
-ve	NULL
)	NULL
IA	NULL
(	NULL
-ve	NULL
)	NULL
40	NULL
40	NULL
Lzsuco	NULL
r-	NULL
.	NULL

_c	NULL
5s	NULL
53	NULL
...	NULL
LD	NULL
(	NULL
-ve	NULL
)	NULL
LS	NULL
(	NULL
ve	NULL
)	NULL
40	NULL
40	NULL
Es	NULL
0	NULL
Loana	NULL
_	NULL
t	NULL
BH	NULL
BS	NULL
,	NULL
Sl	NULL
5490	NULL
Pga	NULL
©4900	NULL
g	NULL
4a	NULL
9	NULL
0	NULL
-	NULL
o	NULL
0	NULL
-	NULL
0	NULL
E	NULL
8	NULL
m	NULL
L_	NULL
]	NULL
L____J	NULL
PHA	NULL
targets	NULL
LCL	NULL
targets	NULL
PHA	NULL
targets	NULL
_	NULL
LCL	NULL
targets	NULL
+	NULL
peptide	NULL
+	NULL
peptide	NULL
+	NULL
peptide	NULL
+	NULL
peptide	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Cytotoxic	NULL
activities	NULL
of	NULL
polyclonal	NULL
effector	NULL
T	NULL
cells	NULL
induced	NULL
by	NULL
peptide-loaded	NULL
autologous	NULL
DC	NULL
stimulation	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Response	NULL
of	NULL
two	NULL
EBV-immune	NULL
donors	NULL
,	NULL
DA	NULL
(	NULL
A2.01	NULL
,	NULL
A11.01	NULL
;	NULL
B7	NULL
,	NULL
B44	NULL
)	NULL
and	NULL
SL	NULL
(	NULL
A1	NULL
,	NULL
A2.01	NULL
;	NULL
B16	NULL
,	NULL
B40.01	NULL
)	NULL
,	NULL
and	NULL
of	NULL
two	NULL
nonimmune	NULL
donors	NULL
,	NULL
CD	NULL
(	NULL
A1	NULL
,	NULL
A2.01	NULL
;	NULL
B37	NULL
,	NULL
B62	NULL
)	NULL
and	NULL
LD	NULL
(	NULL
A2.01	NULL
:	NULL
B51	NULL
,	NULL
B63	NULL
)	NULL
,	NULL
to	NULL
the	NULL
A2.01-restricted	NULL
lytic	NULL
cycle	NULL
epitope	NULL
GLC	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Response	NULL
of	NULL
two	NULL
EBV-immune	NULL
donors	NULL
,	NULL
AR	NULL
(	NULL
A1	NULL
;	NULL
B8	NULL
,	NULL
B57	NULL
)	NULL
and	NULL
MR	NULL
(	NULL
A2.01	NULL
,	NULL
A29	NULL
;	NULL
B8	NULL
,	NULL
B40.01	NULL
)	NULL
and	NULL
of	NULL
two	NULL
nonimmune	NULL
donors	NULL
,	NULL
IA	NULL
(	NULL
A1	NULL
;	NULL
B7	NULL
,	NULL
B8	NULL
)	NULL
and	NULL
LS	NULL
(	NULL
A1	NULL
;	NULL
B8	NULL
)	NULL
,	NULL
to	NULL
the	NULL
B8-restricted	NULL
lytic	NULL
cycle	NULL
epitope	NULL
RAK	NULL
.	NULL

Effector	NULL
T	NULL
cells	NULL
were	NULL
tested	NULL
(	NULL
E/T	NULL
,	NULL
10:1	NULL
)	NULL
on	NULL
autologous	NULL
PHA	NULL
blast	NULL
and	NULL
LCL	NULL
targets	NULL
either	NULL
untreated	NULL
or	NULL
peptide-loaded	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

1.	NULL
ated	NULL
an	NULL
LMP2-specific	NULL
response	NULL
which	NULL
mapped	NULL
entirely	NULL
to	NULL
the	NULL
B40.01-restricted	NULL
epitope	NULL
,	NULL
IEDPPFNSL	NULL
(	NULL
designated	NULL
IED	NULL
)	NULL
,	NULL
with	NULL
no	NULL
detectable	NULL
reactivity	NULL
to	NULL
either	NULL
of	NULL
the	NULL
above	NULL
A2Z.01-restricted	NULL
epitopes	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
LCL	NULL
data	NULL
,	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
this	NULL
case	NULL
,	NULL
stimulation	NULL
with	NULL
peptide-loaded	NULL
DCs	NULL
was	NULL
able	NULL
to	NULL
reactivate	NULL
not	NULL
just	NULL
the	NULL
IED-specific	NULL
reactivity	NULL
but	NULL
also	NULL
a	NULL
significant	NULL
response	NULL
to	NULL
one	NULL
of	NULL
the	NULL
AZ.01-restricted	NULL
epitopes	NULL
,	NULL
LLW	NULL
,	NULL
though	NULL
not	NULL
to	NULL
the	NULL
other	NULL
epitope	NULL
CLG	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
experiments	NULL
were	NULL
then	NULL
extended	NULL
to	NULL
donors	NULL
whose	NULL
polyclonal	NULL
CTL	NULL
response	NULL
to	NULL
LCL	NULL
stimulation	NULL
lacks	NULL
a	NULL
detectable	NULL
LMP2-specific	NULL
component	NULL
and	NULL
is	NULL
dominated	NULL
by	NULL
reactivities	NULL
against	NULL
epitopes	NULL
from	NULL
EBNA3A	NULL
,	NULL
-3B	NULL
,	NULL
and	NULL
-3C	NULL
proteins	NULL
.	NULL

Figure	NULL
6A	NULL
presents	NULL
the	NULL
results	NULL
from	NULL
one	NULL
such	NULL
individual	NULL
,	NULL
RT	NULL
,	NULL
whose	NULL
major	NULL
component	NULL
of	NULL
CTL	NULL
memory	NULL
to	NULL
latent	NULL
cycle	NULL
antigens	NULL
is	NULL
directed	NULL
against	NULL
the	NULL
B27.05-restricted	NULL
CTL	NULL
epitope	NULL
RRI	NULL
from	NULL
EBNA3C	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
LCL	NULL
data	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
therefore	NULL
,	NULL
stimulation	NULL
with	NULL
RRI	NULL
peptide-loaded	NULL
DCs	NULL
was	NULL
able	NULL
to	NULL
induce	NULL
a	NULL
strong	NULL
epitope-specific	NULL
response	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
RRI/DC	NULL
)	NULL
.	NULL

However	NULL
,	NULL
donor	NULL
RT	NULL
is	NULL
also	NULL
positive	NULL
for	NULL
HLA	NULL
A24.02	NULL
,	NULL
a	NULL
potential	NULL
restricting	NULL
element	NULL
for	NULL
a	NULL
defined	NULL
epitope	NULL
TYGPVFMCL	NULL
(	NULL
designated	NULL
TYG	NULL
)	NULL
in	NULL
LMP2	NULL
.	NULL

We	NULL
found	NULL
that	NULL
stimulation	NULL
with	NULL
TYG-loaded	NULL
voL	NULL
.	NULL

73	NULL
,	NULL
1999	NULL
A	NULL
B	NULL
WT	NULL
(	NULL
+ve	NULL
)	NULL
SL	NULL
(	NULL
+ve	NULL
)	NULL
LLW/ADC	NULL
LLWADC	NULL
40	NULL
20	NULL
CLGDC	NULL
IED/DC	NULL
LCL	NULL
40	NULL
20	NULL
PHA	NULL
targets	NULL
LCL	NULL
targets	NULL
LCL	NULL
targets	NULL
+	NULL
peptide	NULL
-	NULL
+	NULL
peptide	NULL
+	NULL
vace	NULL
PHA	NULL
targets	NULL
LCL	NULL
targets	NULL
LCL	NULL
targets	NULL
+	NULL
peptide	NULL
-	NULL
+	NULL
peptide	NULL
+vace	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Cytotoxic	NULL
activities	NULL
of	NULL
polyclonal	NULL
effector	NULL
T	NULL
cells	NULL
induced	NULL
by	NULL
peptide-loaded	NULL
autologous	NULL
DC	NULL
stimulation	NULL
(	NULL
peptide/DC	NULL
)	NULL
or	NULL
by	NULL
autologous	NULL
B95.8	NULL
virus-transformed	NULL
LCL	NULL
stimulation	NULL
(	NULL
LCL	NULL
)	NULL
.	NULL

(	NULL
A	NULL
)	NULL
EBV-immune	NULL
donor	NULL
WT	NULL
(	NULL
HLA-A2.01	NULL
;	NULL
B14	NULL
,	NULL
B15	NULL
)	NULL
responses	NULL
to	NULL
the	NULL
subdominant	NULL
A2.01-restricted	NULL
latent	NULL
cycle	NULL
epitopes	NULL
LLW	NULL
and	NULL
CLG	NULL
(	NULL
both	NULL
from	NULL
LMP2	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
EBV-immune	NULL
donor	NULL
SL	NULL
(	NULL
HLA-A1	NULL
,	NULL
A2.01	NULL
,	NULL
B16	NULL
,	NULL
B40.01	NULL
)	NULL
responses	NULL
to	NULL
the	NULL
subdominant	NULL
A2.01-restricted	NULL
epitope	NULL
LLW	NULL
and	NULL
to	NULL
the	NULL
B40.01-restricted	NULL
epitope	NULL
IED	NULL
(	NULL
both	NULL
from	NULL
LMP2	NULL
)	NULL
.	NULL

Effector	NULL
T	NULL
cells	NULL
were	NULL
tested	NULL
(	NULL
E/T	NULL
,	NULL
10:1	NULL
)	NULL
on	NULL
autologous	NULL
PHA	NULL
blast	NULL
and	NULL
LCL	NULL
targets	NULL
infected	NULL
with	NULL
recombinant	NULL
vaccinia	NULL
viruses	NULL
vTK~	NULL
and	NULL
vLMP2	NULL
(	NULL
expressing	NULL
LMP2	NULL
)	NULL
.	NULL

DCs	NULL
did	NULL
indeed	NULL
selectively	NULL
induce	NULL
a	NULL
specific	NULL
response	NULL
from	NULL
this	NULL
donor	NULL
that	NULL
was	NULL
capable	NULL
of	NULL
recognizing	NULL
both	NULL
exogenously	NULL
loaded	NULL
epitope	NULL
and	NULL
endogenously	NULL
expressed	NULL
LMP2	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
TYG/DC	NULL
)	NULL
,	NULL
even	NULL
though	NULL
such	NULL
effectors	NULL
were	NULL
never	NULL
detected	NULL
in	NULL
LCL-stimulated	NULL
populations	NULL
.	NULL

Analogous	NULL
results	NULL
came	NULL
from	NULL
another	NULL
donor	NULL
,	NULL
DM	NULL
(	NULL
HLA-A1ll-positive	NULL
)	NULL
,	NULL
whose	NULL
polyclonal	NULL
response	NULL
to	NULL
LCL	NULL
stimulation	NULL
is	NULL
largely	NULL
All-restricted	NULL
and	NULL
focused	NULL
on	NULL
the	NULL
IVT	NULL
epitope	NULL
peptide	NULL
derived	NULL
from	NULL
EBNA3B	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
LCL	NULL
data	NULL
)	NULL
.	NULL

Such	NULL
effectors	NULL
are	NULL
also	NULL
efficiently	NULL
reactivated	NULL
by	NULL
stimulation	NULL
with	NULL
IVT-loaded	NULL
DCs	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
IVT/DC	NULL
)	NULL
;	NULL
however	NULL
,	NULL
we	NULL
were	NULL
interested	NULL
to	NULL
know	NULL
whether	NULL
such	NULL
a	NULL
donor	NULL
might	NULL
respond	NULL
to	NULL
a	NULL
subdominant	NULL
All-restricted	NULL
epitope	NULL
SSCSSCPLSKT	NULL
(	NULL
designated	NULL
SSC	NULL
)	NULL
in	NULL
LMP2	NULL
.	NULL

In	NULL
a	NULL
previous	NULL
study	NULL
(	NULL
24	NULL
)	NULL
responses	NULL
to	NULL
this	NULL
epitope	NULL
were	NULL
only	NULL
identified	NULL
in	NULL
A1ll-positive	NULL
individuals	NULL
who	NULL
lack	NULL
dominant	NULL
EBNA3B-specific	NULL
responses	NULL
because	NULL
their	NULL
resident	NULL
virus	NULL
carries	NULL
an	NULL
epitope-loss	NULL
mutation	NULL
in	NULL
the	NULL
EBNA3B	NULL
protein	NULL
(	NULL
18	NULL
)	NULL
.	NULL

We	NULL
in	NULL
fact	NULL
observed	NULL
that	NULL
SSC-specific	NULL
effector	NULL
CTLs	NULL
,	NULL
active	NULL
against	NULL
both	NULL
the	NULL
peptide	NULL
and	NULL
endogenously	NULL
expressed	NULL
LMP2	NULL
protein	NULL
,	NULL
could	NULL
be	NULL
generated	NULL
from	NULL
donor	NULL
DM	NULL
by	NULL
stimulation	NULL
with	NULL
SSC-loaded	NULL
DCs	NULL
DENDRITIC	NULL
CELL	NULL
STIMULATION	NULL
OF	NULL
EBV-SPECIFIC	NULL
T	NULL
CELLS	NULL
-	NULL
339	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
SSC/DC	NULL
)	NULL
;	NULL
such	NULL
effectors	NULL
have	NULL
never	NULL
been	NULL
detected	NULL
in	NULL
polyclonal	NULL
LCL-stimulated	NULL
effectors	NULL
from	NULL
this	NULL
individual	NULL
.	NULL

DISCUSSION	NULL
The	NULL
present	NULL
study	NULL
sought	NULL
to	NULL
avoid	NULL
LCL	NULL
stimulation	NULL
and	NULL
to	NULL
develop	NULL
an	NULL
alternative	NULL
means	NULL
of	NULL
probing	NULL
EBV-specific	NULL
CTL	NULL
memory	NULL
that	NULL
was	NULL
efficient	NULL
and	NULL
that	NULL
allowed	NULL
even	NULL
rare	NULL
components	NULL
of	NULL
the	NULL
memory	NULL
pool	NULL
to	NULL
be	NULL
accessed	NULL
without	NULL
laborious	NULL
cell	NULL
cloning	NULL
.	NULL

Experiments	NULL
in	NULL
the	NULL
influenza	NULL
virus	NULL
system	NULL
had	NULL
first	NULL
shown	NULL
that	NULL
individual	NULL
epitope	NULL
specificities	NULL
could	NULL
be	NULL
reactivated	NULL
in	NULL
vitro	NULL
by	NULL
stimulation	NULL
with	NULL
epitope	NULL
peptides	NULL
and	NULL
expanded	NULL
thereafter	NULL
as	NULL
bulk	NULL
effector	NULL
populations	NULL
in	NULL
IL-2	NULL
(	NULL
20	NULL
,	NULL
30	NULL
)	NULL
.	NULL

However	NULL
,	NULL
those	NULL
studies	NULL
,	NULL
which	NULL
used	NULL
PBMCs	NULL
as	NULL
a	NULL
source	NULL
both	NULL
of	NULL
peptide-loaded	NULL
stimulator	NULL
and	NULL
of	NULL
responder	NULL
cells	NULL
,	NULL
were	NULL
limited	NULL
to	NULL
immunodominant	NULL
epitopes	NULL
.	NULL

In	NULL
the	NULL
EBV	NULL
system	NULL
also	NULL
,	NULL
such	NULL
a	NULL
protocol	NULL
can	NULL
reactivate	NULL
CTL	NULL
memory	NULL
to	NULL
immunodominant	NULL
latent	NULL
cycle	NULL
epitopes	NULL
(	NULL
13	NULL
,	NULL
23	NULL
)	NULL
,	NULL
but	NULL
in	NULL
our	NULL
experience	NULL
it	NULL
has	NULL
been	NULL
much	NULL
more	NULL
difficult	NULL
to	NULL
access	NULL
low-frequency	NULL
subdominant	NULL
components	NULL
of	NULL
CTL	NULL
memory	NULL
as	NULL
bulk	NULL
effector	NULL
populations	NULL
in	NULL
this	NULL
way	NULL
(	NULL
23a	NULL
)	NULL
.	NULL

It	NULL
is	NULL
only	NULL
as	NULL
rare	NULL
clones	NULL
in	NULL
limiting	NULL
dilution	NULL
assays	NULL
that	NULL
such	NULL
subdominant	NULL
components	NULL
become	NULL
detectable	NULL
after	NULL
conventional	NULL
peptide	NULL
stimulation	NULL
(	NULL
50	NULL
)	NULL
and	NULL
,	NULL
even	NULL
then	NULL
,	NULL
recent	NULL
evidence	NULL
suggests	NULL
that	NULL
the	NULL
limiting	NULL
dilution	NULL
approach	NULL
may	NULL
not	NULL
be	NULL
accessing	NULL
all	NULL
memory	NULL
cells	NULL
with	NULL
the	NULL
relevant	NULL
peptide	NULL
speci-ficity	NULL
(	NULL
14	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
set	NULL
out	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
efficiency	NULL
of	NULL
EBV	NULL
epitope	NULL
peptide	NULL
stimulation	NULL
could	NULL
be	NULL
improved	NULL
by	NULL
using	NULL
DC	NULL
preparations	NULL
as	NULL
the	NULL
source	NULL
of	NULL
stimulator	NULL
cells	NULL
.	NULL

This	NULL
was	NULL
prompted	NULL
by	NULL
the	NULL
mounting	NULL
evidence	NULL
on	NULL
the	NULL
potency	NULL
of	NULL
DCs	NULL
as	NULL
APCs	NULL
both	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
(	NULL
reviewed	NULL
reference	NULL
5	NULL
)	NULL
.	NULL

Thus	NULL
CD8*	NULL
CTL	NULL
responses	NULL
can	NULL
be	NULL
elicited	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
mouse	NULL
model	NULL
systems	NULL
by	NULL
DCs	NULL
expressing	NULL
the	NULL
antigen	NULL
endogenously	NULL
from	NULL
viral	NULL
or	NULL
plasmid	NULL
vectors	NULL
(	NULL
12	NULL
,	NULL
17	NULL
,	NULL
44	NULL
,	NULL
47	NULL
,	NULL
48	NULL
,	NULL
54	NULL
)	NULL
,	NULL
or	NULL
preexposed	NULL
to	NULL
exogenous	NULL
antigen	NULL
in	NULL
such	NULL
a	NULL
way	NULL
as	NULL
to	NULL
encourage	NULL
its	NULL
entry	NULL
into	NULL
the	NULL
MHC	NULL
class	NULL
I	NULL
pathway	NULL
(	NULL
1	NULL
,	NULL
3	NULL
,	NULL
11	NULL
,	NULL
35	NULL
,	NULL
46	NULL
,	NULL
57	NULL
)	NULL
,	NULL
or	NULL
preloaded	NULL
with	NULL
epitope	NULL
peptides	NULL
(	NULL
16	NULL
,	NULL
27	NULL
,	NULL
31	NULL
)	NULL
.	NULL

Studies	NULL
to	NULL
date	NULL
in	NULL
human	NULL
systems	NULL
are	NULL
more	NULL
limited	NULL
and	NULL
most	NULL
in	NULL
vitro	NULL
work	NULL
has	NULL
focused	NULL
on	NULL
DC	NULL
presentation	NULL
of	NULL
melanoma-associated	NULL
target	NULL
antigens	NULL
or	NULL
of	NULL
epitope	NULL
peptides	NULL
,	NULL
usually	NULL
HLA-A2.01	NULL
restricted	NULL
,	NULL
derived	NULL
from	NULL
such	NULL
antigens	NULL
(	NULL
4	NULL
,	NULL
34	NULL
,	NULL
52	NULL
,	NULL
53	NULL
,	NULL
55	NULL
)	NULL
.	NULL

Here	NULL
a	NULL
number	NULL
of	NULL
groups	NULL
have	NULL
shown	NULL
that	NULL
an	NULL
initial	NULL
stimulus	NULL
with	NULL
peptide-loaded	NULL
DCs	NULL
followed	NULL
by	NULL
several	NULL
repeat	NULL
stimulations	NULL
,	NULL
usually	NULL
involving	NULL
adherent	NULL
monocytes	NULL
as	NULL
presenting	NULL
cells	NULL
,	NULL
can	NULL
generate	NULL
bulk	NULL
T-cell	NULL
populations	NULL
which	NULL
contain	NULL
epitope-specific	NULL
reactivity	NULL
and	NULL
which	NULL
frequently	NULL
also	NULL
recognize	NULL
melanoma	NULL
cell	NULL
lines	NULL
endogenously	NULL
expressing	NULL
the	NULL
relevant	NULL
antigen	NULL
.	NULL

Our	NULL
study	NULL
used	NULL
a	NULL
DC-based	NULL
in	NULL
vitro	NULL
stimulation	NULL
protocol	NULL
which	NULL
is	NULL
essentially	NULL
similar	NULL
in	NULL
design	NULL
to	NULL
those	NULL
used	NULL
in	NULL
the	NULL
melanoma	NULL
studies	NULL
.	NULL

We	NULL
first	NULL
sought	NULL
to	NULL
validate	NULL
this	NULL
protocol	NULL
by	NULL
testing	NULL
the	NULL
capacity	NULL
of	NULL
DCs	NULL
to	NULL
reactivate	NULL
CTL	NULL
responses	NULL
against	NULL
immunodominant	NULL
EBV	NULL
latent	NULL
cycle	NULL
epitopes	NULL
.	NULL

Using	NULL
virus-im-mune	NULL
donors	NULL
known	NULL
to	NULL
possess	NULL
the	NULL
relevant	NULL
reactivities	NULL
,	NULL
we	NULL
found	NULL
that	NULL
peptide-loaded	NULL
DCs	NULL
are	NULL
quantitatively	NULL
at	NULL
least	NULL
as	NULL
efficient	NULL
at	NULL
reactivating	NULL
these	NULL
immunodominant	NULL
responses	NULL
as	NULL
is	NULL
LCL	NULL
stimulation	NULL
itself	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Furthermore	NULL
the	NULL
peptide-DC	NULL
protocol	NULL
allows	NULL
reactivities	NULL
that	NULL
are	NULL
codominant	NULL
in	NULL
CTL	NULL
memory	NULL
to	NULL
be	NULL
accessed	NULL
individually	NULL
;	NULL
such	NULL
selective	NULL
access	NULL
can	NULL
only	NULL
be	NULL
achieved	NULL
by	NULL
LCL	NULL
stimulation	NULL
in	NULL
rare	NULL
cases	NULL
:	NULL
for	NULL
instance	NULL
,	NULL
where	NULL
LCLs	NULL
are	NULL
available	NULL
carrying	NULL
an	NULL
EBV	NULL
isolate	NULL
with	NULL
a	NULL
natural	NULL
mutation	NULL
in	NULL
one	NULL
or	NULL
more	NULL
of	NULL
the	NULL
immunodominant	NULL
epitope	NULL
sequences	NULL
(	NULL
2	NULL
,	NULL
18	NULL
)	NULL
.	NULL

These	NULL
initial	NULL
experiments	NULL
also	NULL
showed	NULL
that	NULL
DCs	NULL
were	NULL
more	NULL
efficient	NULL
than	NULL
PBMCs	NULL
as	NULL
stimulators	NULL
of	NULL
peptide-induced	NULL
responses	NULL
.	NULL

As	NULL
illustrated	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
with	NULL
three	NULL
epitope	NULL
peptides	NULL
relevant	NULL
to	NULL
donor	NULL
CMc	NULL
,	NULL
only	NULL
the	NULL
two	NULL
most	NULL
abundant	NULL
components	NULL
of	NULL
latent-antigen-specific	NULL
memory	NULL
(	NULL
to	NULL
the	NULL
340	NULL
REDCHENKO	NULL
AND	NULL
RICKINSON	NULL
A	NULL
RT	NULL
(	NULL
+ve	NULL
)	NULL
TYGDC	NULL
|	NULL
40	NULL
RRIDC	NULL
40	NULL
LCL	NULL
©	NULL
2	NULL
z	NULL
0	NULL
€	NULL
9	NULL
0	NULL
£	NULL
9	NULL
&	NULL
te	NULL
3	NULL
m	NULL
§	NULL
Br	NULL
SER	NULL
$	NULL
93	NULL
PHA	NULL
targets	NULL
LCL	NULL
targets	NULL
LCL	NULL
targets	NULL
+	NULL
peptide	NULL
+	NULL
peptide	NULL
+	NULL
vace	NULL
J.	NULL
Virou	NULL
.	NULL

B	NULL
DM	NULL
(	NULL
+ve	NULL
)	NULL
[	NULL
J	NULL
SsCmDC	NULL
40	NULL
7	NULL
o	NULL
IvT/DC	NULL
|	NULL
40	NULL
LCL	NULL
40	NULL
PHA	NULL
targets	NULL
LCL	NULL
targets	NULL
LCL	NULL
targets	NULL
+	NULL
peptide	NULL
_	NULL
+	NULL
peptide	NULL
+	NULL
vace	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Cytotoxic	NULL
activities	NULL
of	NULL
polyclonal	NULL
effector	NULL
T	NULL
cells	NULL
induced	NULL
by	NULL
peptide-loaded	NULL
autologous	NULL
DC	NULL
stimulation	NULL
(	NULL
peptide/DC	NULL
)	NULL
or	NULL
by	NULL
autologous	NULL
B95.8	NULL
virus-transformed	NULL
LCL	NULL
stimulation	NULL
(	NULL
LCL	NULL
)	NULL
.	NULL

(	NULL
A	NULL
)	NULL
EBV-immune	NULL
donor	NULL
RT	NULL
(	NULL
HLA-A2.01	NULL
,	NULL
A24.02	NULL
;	NULL
B27.05	NULL
,	NULL
B35.01	NULL
)	NULL
responses	NULL
to	NULL
the	NULL
subdominant	NULL
A24.02-restricted	NULL
latent-cycle	NULL
epitope	NULL
TYG	NULL
(	NULL
from	NULL
LMP2	NULL
)	NULL
and	NULL
to	NULL
the	NULL
immunodominant	NULL
B27.05-restricted	NULL
latent	NULL
cycle	NULL
epitope	NULL
RRI	NULL
(	NULL
from	NULL
EBNA3C	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
EBV-immune	NULL
donor	NULL
DM	NULL
(	NULL
HLA-A1	NULL
,	NULL
A11.01	NULL
;	NULL
B8	NULL
,	NULL
B57	NULL
)	NULL
responses	NULL
to	NULL
two	NULL
A1ll-restricted	NULL
latent	NULL
cycle	NULL
epitopes	NULL
,	NULL
the	NULL
subdominant	NULL
epitope	NULL
SSC	NULL
(	NULL
from	NULL
LMP2	NULL
)	NULL
and	NULL
the	NULL
immunodominant	NULL
epitope	NULL
IVT	NULL
(	NULL
from	NULL
EBNA3B	NULL
)	NULL
.	NULL

Effector	NULL
T	NULL
cells	NULL
were	NULL
tested	NULL
(	NULL
E/T	NULL
,	NULL
10:1	NULL
)	NULL
on	NULL
autologous	NULL
PHA	NULL
blast	NULL
and	NULL
LCL	NULL
targets	NULL
either	NULL
untreated	NULL
or	NULL
peptide	NULL
loaded	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
or	NULL
on	NULL
LCL	NULL
targets	NULL
infected	NULL
with	NULL
recombinant	NULL
vaccinia	NULL
viruses	NULL
vTK	NULL
~	NULL
,	NULL
vE3B	NULL
(	NULL
expressing	NULL
EBNA3B	NULL
)	NULL
,	NULL
vE3C	NULL
(	NULL
expressing	NULL
EBNA3C	NULL
)	NULL
,	NULL
or	NULL
vLMP2	NULL
(	NULL
expressing	NULL
LMP2	NULL
)	NULL
.	NULL

QAK	NULL
and	NULL
IVT	NULL
epitopes	NULL
)	NULL
could	NULL
be	NULL
accessed	NULL
as	NULL
bulk	NULL
effectors	NULL
by	NULL
PBMC	NULL
stimulators	NULL
;	NULL
by	NULL
comparison	NULL
,	NULL
DC	NULL
stimulation	NULL
not	NULL
only	NULL
produced	NULL
more	NULL
potent	NULL
effector	NULL
populations	NULL
specific	NULL
for	NULL
these	NULL
epitopes	NULL
but	NULL
also	NULL
generated	NULL
a	NULL
significant	NULL
response	NULL
from	NULL
memory	NULL
CTLs	NULL
to	NULL
a	NULL
third	NULL
epitope	NULL
,	NULL
AVF	NULL
.	NULL

Throughout	NULL
these	NULL
initial	NULL
experiments	NULL
,	NULL
it	NULL
is	NULL
important	NULL
to	NULL
note	NULL
that	NULL
the	NULL
effectors	NULL
induced	NULL
by	NULL
peptide-loaded	NULL
DCs	NULL
were	NULL
capable	NULL
of	NULL
recognizing	NULL
naturally	NULL
processed	NULL
antigen	NULL
as	NULL
well	NULL
as	NULL
epitope	NULL
peptide	NULL
.	NULL

Thus	NULL
,	NULL
these	NULL
CTLs	NULL
killed	NULL
LCL	NULL
targets	NULL
,	NULL
expressing	NULL
the	NULL
relevant	NULL
EBV	NULL
latent	NULL
cycle	NULL
target	NULL
antigen	NULL
,	NULL
as	NULL
efficiently	NULL
as	NULL
did	NULL
LCL-stimulated	NULL
effectors	NULL
and	NULL
displayed	NULL
incremental	NULL
lysis	NULL
when	NULL
the	NULL
level	NULL
of	NULL
that	NULL
target	NULL
antigen	NULL
was	NULL
selectively	NULL
increased	NULL
by	NULL
expression	NULL
from	NULL
a	NULL
recombinant	NULL
vaccinia	NULL
vector	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

Such	NULL
pilot	NULL
experiments	NULL
allowed	NULL
us	NULL
to	NULL
optimize	NULL
a	NULL
stimulation	NULL
protocol	NULL
with	NULL
which	NULL
to	NULL
probe	NULL
EBV-induced	NULL
CTL	NULL
memory	NULL
for	NULL
reactivities	NULL
that	NULL
would	NULL
not	NULL
be	NULL
efficiently	NULL
accessed	NULL
by	NULL
LCL	NULL
stimulation	NULL
.	NULL

A	NULL
first	NULL
important	NULL
question	NULL
in	NULL
this	NULL
regard	NULL
concerned	NULL
memory	NULL
to	NULL
lytic	NULL
cycle	NULL
antigens	NULL
,	NULL
since	NULL
recent	NULL
work	NULL
on	NULL
IM	NULL
patients	NULL
has	NULL
revealed	NULL
that	NULL
primary	NULL
EBV	NULL
infection	NULL
is	NULL
accompanied	NULL
by	NULL
unusually	NULL
strong	NULL
responses	NULL
of	NULL
this	NULL
kind	NULL
(	NULL
14	NULL
,	NULL
49	NULL
)	NULL
;	NULL
this	NULL
implies	NULL
that	NULL
such	NULL
reactivities	NULL
may	NULL
be	NULL
present	NULL
,	NULL
albeit	NULL
undetected	NULL
,	NULL
in	NULL
long-term	NULL
virus	NULL
carriers	NULL
.	NULL

Here	NULL
we	NULL
focused	NULL
on	NULL
two	NULL
epitope-HLA	NULL
combinations	NULL
(	NULL
GLC/A2.01	NULL
and	NULL
RAK/B8	NULL
)	NULL
known	NULL
to	NULL
be	NULL
immu-	NULL
nodominant	NULL
targets	NULL
of	NULL
the	NULL
primary	NULL
CTL	NULL
response	NULL
in	NULL
IM	NULL
patients	NULL
of	NULL
the	NULL
relevant	NULL
HLA	NULL
type	NULL
(	NULL
14	NULL
,	NULL
49	NULL
)	NULL
and	NULL
on	NULL
two	NULL
other	NULL
combinations	NULL
(	NULL
TLD/A2.01	NULL
and	NULL
APE/B35.01	NULL
)	NULL
which	NULL
appear	NULL
to	NULL
be	NULL
subdominant	NULL
targets	NULL
in	NULL
that	NULL
the	NULL
relevant	NULL
reactivities	NULL
are	NULL
only	NULL
detectable	NULL
in	NULL
IM	NULL
effector	NULL
populations	NULL
after	NULL
extensive	NULL
screening	NULL
of	NULL
in	NULL
vitro-derived	NULL
clones	NULL
(	NULL
1a	NULL
)	NULL
.	NULL

Stimulation	NULL
with	NULL
peptide-loaded	NULL
DCs	NULL
revealed	NULL
,	NULL
for	NULL
each	NULL
of	NULL
these	NULL
four	NULL
epitopes	NULL
,	NULL
the	NULL
existence	NULL
of	NULL
a	NULL
specific	NULL
memory	NULL
CTL	NULL
response	NULL
in	NULL
healthy	NULL
virus	NULL
carriers	NULL
with	NULL
the	NULL
appropriate	NULL
HLA	NULL
type	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

This	NULL
work	NULL
adds	NULL
significantly	NULL
to	NULL
the	NULL
original	NULL
study	NULL
of	NULL
Bogedain	NULL
et	NULL
al	NULL
.	NULL

(	NULL
8	NULL
)	NULL
who	NULL
used	NULL
in	NULL
vitro	NULL
stimulation	NULL
with	NULL
pooled	NULL
peptides	NULL
from	NULL
the	NULL
sequence	NULL
of	NULL
the	NULL
immediate-early	NULL
lytic	NULL
cycle	NULL
protein	NULL
BZLFI	NULL
and	NULL
,	NULL
without	NULL
including	NULL
DCs	NULL
in	NULL
the	NULL
protocol	NULL
,	NULL
elicited	NULL
a	NULL
memory	NULL
response	NULL
from	NULL
a	NULL
B8-positive	NULL
donor	NULL
which	NULL
was	NULL
subsequently	NULL
mapped	NULL
to	NULL
the	NULL
RAK	NULL
epitope	NULL
.	NULL

We	NULL
have	NULL
indeed	NULL
confirmed	NULL
that	NULL
RAK-	NULL
(	NULL
and	NULL
also	NULL
GLC-	NULL
)	NULL
specific	NULL
memory	NULL
responses	NULL
can	NULL
be	NULL
reactivated	NULL
by	NULL
peptide	NULL
stimulation	NULL
alone	NULL
(	NULL
1a	NULL
)	NULL
,	NULL
a	NULL
fact	NULL
we	NULL
presume	NULL
to	NULL
reflect	NULL
the	NULL
unusual	NULL
strength	NULL
of	NULL
these	NULL
particular	NULL
responses	NULL
(	NULL
14	NULL
)	NULL
.	NULL

These	NULL
two	NULL
studies	NULL
,	NULL
and	NULL
recent	NULL
evidence	NULL
from	NULL
T	NULL
cells	NULL
cloned	NULL
from	NULL
the	NULL
synovium	NULL
of	NULL
EBV-carrying	NULL
rheumatoid	NULL
arthritis	NULL
patients	NULL
(	NULL
45	NULL
)	NULL
,	NULL
make	NULL
it	NULL
clear	NULL
that	NULL
lytic-antigen-specific	NULL
responses	NULL
are	NULL
not	NULL
confined	NULL
to	NULL
primary	NULL
infection	NULL
but	NULL
are	NULL
maintained	NULL
throughout	NULL
life	NULL
.	NULL

This	NULL
strongly	NULL
suggests	NULL
that	NULL
virus	NULL
repli-	NULL
voL	NULL
.	NULL

73	NULL
,	NULL
1999	NULL
cative	NULL
lesions	NULL
,	NULL
whose	NULL
persistence	NULL
in	NULL
the	NULL
oropharynx	NULL
is	NULL
a	NULL
feature	NULL
of	NULL
the	NULL
asymptomatic	NULL
carrier	NULL
state	NULL
(	NULL
37	NULL
)	NULL
,	NULL
remain	NULL
under	NULL
direct	NULL
T-cell	NULL
control	NULL
.	NULL

It	NULL
is	NULL
worth	NULL
noting	NULL
,	NULL
however	NULL
,	NULL
that	NULL
these	NULL
conclusions	NULL
are	NULL
only	NULL
valid	NULL
if	NULL
the	NULL
responses	NULL
observed	NULL
in	NULL
vitro	NULL
are	NULL
being	NULL
generated	NULL
from	NULL
antigen-experienced	NULL
rather	NULL
than	NULL
naive	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
rep-ertoire	NULL
.	NULL

This	NULL
is	NULL
a	NULL
particularly	NULL
important	NULL
issue	NULL
to	NULL
resolve	NULL
because	NULL
there	NULL
are	NULL
reports	NULL
that	NULL
peptide-loaded	NULL
DCs	NULL
can	NULL
initiate	NULL
primary	NULL
responses	NULL
in	NULL
vitro	NULL
not	NULL
just	NULL
in	NULL
murine	NULL
systems	NULL
but	NULL
also	NULL
occasion-ally	NULL
,	NULL
with	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
peptides	NULL
,	NULL
in	NULL
humans	NULL
(	NULL
28	NULL
,	NULL
32	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
in	NULL
vitro	NULL
CTL	NULL
responses	NULL
to	NULL
melanoma-associated	NULL
epitope	NULL
peptides	NULL
are	NULL
frequently	NULL
reported	NULL
even	NULL
from	NULL
healthy	NULL
donors	NULL
(	NULL
39	NULL
,	NULL
56	NULL
)	NULL
,	NULL
and	NULL
it	NULL
is	NULL
not	NULL
known	NULL
whether	NULL
this	NULL
reflects	NULL
a	NULL
primary	NULL
response	NULL
or	NULL
some	NULL
preexisting	NULL
T-cell	NULL
immunity	NULL
to	NULL
``	NULL
self	NULL
``	NULL
peptides	NULL
from	NULL
lineage-restricted	NULL
cellular	NULL
proteins	NULL
.	NULL

Our	NULL
studies	NULL
with	NULL
EBV-seronegative	NULL
donors	NULL
by	NULL
using	NULL
immunodominant	NULL
latent-cycle	NULL
(	NULL
FLR/B8	NULL
and	NULL
QAK/B8	NULL
)	NULL
and	NULL
lytic-cycle	NULL
(	NULL
GLC/A2.01	NULL
and	NULL
RAK/B8	NULL
)	NULL
epitopes	NULL
suggest	NULL
that	NULL
primary	NULL
responses	NULL
are	NULL
not	NULL
detectable	NULL
when	NULL
using	NULL
our	NULL
particular	NULL
DC	NULL
stimulation	NULL
protocol	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
and	NULL
4	NULL
)	NULL
.	NULL

Where	NULL
primary	NULL
human	NULL
CTL	NULL
responses	NULL
to	NULL
microbial	NULL
peptides	NULL
have	NULL
been	NULL
elicited	NULL
in	NULL
vitro	NULL
,	NULL
with	NULL
or	NULL
without	NULL
DCs	NULL
as	NULL
stimulator	NULL
cells	NULL
,	NULL
the	NULL
protocols	NULL
have	NULL
involved	NULL
either	NULL
multiple	NULL
restimulation	NULL
of	NULL
purified	NULL
CD8	NULL
*	NULL
T-cell	NULL
responders	NULL
(	NULL
32	NULL
)	NULL
or	NULL
extensive	NULL
screening	NULL
of	NULL
the	NULL
PBMC	NULL
response	NULL
by	NULL
cloning	NULL
(	NULL
36	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
our	NULL
protocol	NULL
involves	NULL
a	NULL
limited	NULL
number	NULL
of	NULL
stimulations	NULL
of	NULL
the	NULL
entire	NULL
PBMC	NULL
population	NULL
and	NULL
analysis	NULL
of	NULL
the	NULL
reactive	NULL
cells	NULL
in	NULL
bulk	NULL
.	NULL

A	NULL
second	NULL
important	NULL
application	NULL
of	NULL
the	NULL
peptide-DC	NULL
stimulation	NULL
protocol	NULL
is	NULL
in	NULL
the	NULL
selective	NULL
reactivation	NULL
of	NULL
responses	NULL
to	NULL
subdominant	NULL
latent	NULL
cycle	NULL
proteins	NULL
,	NULL
in	NULL
particular	NULL
proteins	NULL
which	NULL
constitute	NULL
potentially	NULL
useful	NULL
targets	NULL
for	NULL
the	NULL
immune	NULL
therapy	NULL
of	NULL
virus-associated	NULL
tumours	NULL
(	NULL
38	NULL
)	NULL
.	NULL

Of	NULL
the	NULL
few	NULL
EBV	NULL
latent-cycle	NULL
proteins	NULL
constitutively	NULL
expressed	NULL
in	NULL
EBV-positive	NULL
malignancies	NULL
,	NULL
such	NULL
as	NULL
NPC	NULL
,	NULL
LMP2	NULL
is	NULL
arguably	NULL
the	NULL
best	NULL
candidate	NULL
target	NULL
antigen	NULL
(	NULL
24	NULL
)	NULL
,	NULL
and	NULL
yet	NULL
CTLs	NULL
reactive	NULL
to	NULL
this	NULL
protein	NULL
are	NULL
almost	NULL
always	NULL
minor	NULL
components	NULL
of	NULL
the	NULL
memory	NULL
response	NULL
induced	NULL
by	NULL
virus	NULL
infection	NULL
(	NULL
22	NULL
,	NULL
33	NULL
)	NULL
.	NULL

Here	NULL
we	NULL
show	NULL
that	NULL
DCs	NULL
loaded	NULL
with	NULL
LMP2	NULL
epitope	NULL
peptides	NULL
are	NULL
capable	NULL
of	NULL
eliciting	NULL
epitope-specific	NULL
CTL	NULL
responses	NULL
in	NULL
vitro	NULL
from	NULL
donors	NULL
for	NULL
whom	NULL
the	NULL
conventional	NULL
LCL-induced	NULL
response	NULL
contains	NULL
little	NULL
if	NULL
any	NULL
of	NULL
the	NULL
relevant	NULL
LMP2	NULL
reactivity	NULL
.	NULL

We	NULL
tested	NULL
five	NULL
different	NULL
LMP2	NULL
epitope-HLA	NULL
class	NULL
I	NULL
combinations	NULL
in	NULL
this	NULL
way	NULL
and	NULL
for	NULL
each	NULL
we	NULL
obtained	NULL
positive	NULL
responses	NULL
in	NULL
most	NULL
(	NULL
but	NULL
not	NULL
all	NULL
)	NULL
of	NULL
the	NULL
individuals	NULL
tested	NULL
with	NULL
the	NULL
relevant	NULL
HLA	NULL
type	NULL
.	NULL

It	NULL
is	NULL
encouraging	NULL
to	NULL
note	NULL
that	NULL
the	NULL
range	NULL
of	NULL
restriction	NULL
elements	NULL
presenting	NULL
LMP2	NULL
epitopes	NULL
includes	NULL
some	NULL
alleles	NULL
(	NULL
HLA-A11.01	NULL
,	NULL
-A24.02	NULL
,	NULL
and	NULL
-B40.01	NULL
)	NULL
which	NULL
are	NULL
common	NULL
in	NULL
the	NULL
Southeast	NULL
Asian	NULL
population	NULL
,	NULL
where	NULL
NPC	NULL
is	NULL
seen	NULL
in	NULL
particularly	NULL
high	NULL
frequency	NULL
(	NULL
24	NULL
)	NULL
.	NULL

This	NULL
opens	NULL
up	NULL
the	NULL
possibility	NULL
of	NULL
using	NULL
epitope	NULL
peptide-loaded	NULL
DCs	NULL
therapeutically	NULL
as	NULL
stimulators	NULL
of	NULL
memory	NULL
T	NULL
cells	NULL
with	NULL
the	NULL
capacity	NULL
to	NULL
recognize	NULL
and	NULL
destroy	NULL
tumor	NULL
cells	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
the	NULL
Cancer	NULL
Research	NULL
Campaign	NULL
,	NULL
Lon-don	NULL
,	NULL
United	NULL
Kingdom	NULL
.	NULL

We	NULL
are	NULL
grateful	NULL
to	NULL
Deborah	NULL
Williams	NULL
for	NULL
excellent	NULL
secretarial	NULL
help	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Albert	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
B.	NULL
Sauter	NULL
,	NULL
and	NULL
N.	NULL
Bhardwaj	NULL
.	NULL

1998	NULL
.	NULL

Dendritic	NULL
cells	NULL
acquire	NULL
antigen	NULL
from	NULL
apoptotic	NULL
cells	NULL
and	NULL
induce	NULL
class	NULL
I	NULL
restricted	NULL
CTLs	NULL
.	NULL

Nature	NULL
392:86-89	NULL
.	NULL

1a.Annels	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
.	NULL

Unpublished	NULL
data	NULL
.	NULL

2	NULL
.	NULL

Apolloni	NULL
,	NULL
A.	NULL
,	NULL
D.	NULL
Moss	NULL
,	NULL
R.	NULL
Stumm	NULL
,	NULL
S.	NULL
Burrows	NULL
,	NULL
A.	NULL
Subrbier	NULL
,	NULL
I	NULL
Misko	NULL
,	NULL
C.	NULL
Schmidt	NULL
,	NULL
and	NULL
T.	NULL
Sculley	NULL
.	NULL

1992	NULL
.	NULL

Sequence	NULL
variation	NULL
of	NULL
cytotoxic	NULL
T	NULL
cell	NULL
epitopes	NULL
in	NULL
different	NULL
isolates	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

22:183-189	NULL
.	NULL

3	NULL
.	NULL

Bachmann	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
M.	NULL
B.	NULL
Lutz	NULL
,	NULL
G.	NULL
T.	NULL
Layton	NULL
,	NULL
S.	NULL
J.	NULL
Harris	NULL
,	NULL
T.	NULL
Febr	NULL
,	NULL
M.	NULL
DENDRITIC	NULL
CELL	NULL
STIMULATION	NULL
OF	NULL
EBV-SPECIFIC	NULL
T	NULL
CELLS	NULL
|	NULL
341	NULL
Rescigno	NULL
,	NULL
and	NULL
P.	NULL
Ricciardicastagnoli	NULL
.	NULL

1996	NULL
.	NULL

Dendritic	NULL
cells	NULL
process	NULL
exogenous	NULL
viral	NULL
proteins	NULL
and	NULL
virus-like	NULL
particles	NULL
for	NULL
class	NULL
I	NULL
presentation	NULL
to	NULL
CD8	NULL
(	NULL
+	NULL
)	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

26:2595-2600	NULL
.	NULL

4	NULL
.	NULL

Bakker	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
H.	NULL
,	NULL
G.	NULL
Marland	NULL
,	NULL
A.	NULL
J.	NULL
Deboer	NULL
,	NULL
R.	NULL
J.	NULL
F.	NULL
Huijbens	NULL
,	NULL
E.	NULL
H.	NULL
J.	NULL
Danen	NULL
,	NULL
G.	NULL
J.	NULL
Adema	NULL
,	NULL
and	NULL
C.	NULL
G.	NULL
Figdor	NULL
.	NULL

1995	NULL
.	NULL

Generation	NULL
of	NULL
anti-melanoma	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
from	NULL
healthy	NULL
donors	NULL
after	NULL
presentation	NULL
of	NULL
melanoma-associated	NULL
antigen-derived	NULL
epitopes	NULL
by	NULL
dendritic	NULL
cells	NULL
in	NULL
vitro	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

55	NULL
:	NULL
5330-5334	NULL
.	NULL

5	NULL
.	NULL

Banchereau	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Steinman	NULL
.	NULL

1998	NULL
.	NULL

Dendritic	NULL
cells	NULL
and	NULL
the	NULL
control	NULL
of	NULL
immunity	NULL
.	NULL

Nature	NULL
392:245-252	NULL
.	NULL

6	NULL
.	NULL

Bender	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
Sapp	NULL
,	NULL
G.	NULL
Schuler	NULL
,	NULL
R.	NULL
M.	NULL
Steinman	NULL
,	NULL
and	NULL
N.	NULL
Bhardwaj	NULL
.	NULL

1996	NULL
.	NULL

Improved	NULL
methods	NULL
for	NULL
the	NULL
generation	NULL
of	NULL
dendritic	NULL
cells	NULL
from	NULL
non-prolifer-ating	NULL
progenitors	NULL
in	NULL
human	NULL
blood	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

Methods	NULL
196:121-135	NULL
.	NULL

7	NULL
.	NULL

Blake	NULL
,	NULL
N.	NULL
,	NULL
S.	NULL
P.	NULL
Lee	NULL
,	NULL
I.	NULL
Redchenko	NULL
,	NULL
W.	NULL
A.	NULL
Thomas	NULL
,	NULL
N.	NULL
Steven	NULL
,	NULL
A.	NULL
Leese	NULL
,	NULL
P.	NULL
M.	NULL
Steigerwald-Mullen	NULL
,	NULL
M.	NULL
G.	NULL
Kurilla	NULL
,	NULL
L.	NULL
Frappier	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
.	NULL

1997	NULL
.	NULL

Human	NULL
CD8	NULL
(	NULL
+	NULL
)	NULL
T	NULL
cell	NULL
responses	NULL
to	NULL
EBV	NULL
EBNA1	NULL
:	NULL
HLA	NULL
class	NULL
I	NULL
presentation	NULL
of	NULL
the	NULL
(	NULL
Gly-Ala	NULL
)	NULL
-containing	NULL
protein	NULL
requires	NULL
exogenous	NULL
processing	NULL
.	NULL

Immunity	NULL
7:791-802	NULL
.	NULL

8	NULL
.	NULL

Bogedain	NULL
,	NULL
C.	NULL
,	NULL
H.	NULL
Wolf	NULL
,	NULL
S.	NULL
Modrow	NULL
,	NULL
G.	NULL
Stuber	NULL
,	NULL
and	NULL
W.	NULL
Jilg	NULL
.	NULL

1995	NULL
.	NULL

Specific	NULL
cytotoxic	NULL
T-lymphocytes	NULL
recognize	NULL
the	NULL
immediate-early	NULL
transactivator	NULL
ZTA	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

69:4872-4879	NULL
.	NULL

9	NULL
.	NULL

Brooks	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
R.	NULL
A.	NULL
Colbert	NULL
,	NULL
J.	NULL
P.	NULL
Mear	NULL
,	NULL
A.	NULL
Leese	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
.	NULL

HLA-B27	NULL
subtype	NULL
polymorphism	NULL
and	NULL
CTL	NULL
epitope	NULL
choice	NULL
:	NULL
studies	NULL
with	NULL
EBV	NULL
peptides	NULL
link	NULL
immunogenicity	NULL
with	NULL
stability	NULL
of	NULL
the	NULL
B27	NULL
:	NULL
peptide	NULL
complex	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
in	NULL
press	NULL
.	NULL

10	NULL
.	NULL

Brooks	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
R.	NULL
J.	NULL
Murray	NULL
,	NULL
W.	NULL
A.	NULL
Thomas	NULL
,	NULL
M.	NULL
G.	NULL
Kurilla	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
.	NULL

1993	NULL
.	NULL

Different	NULL
HLA-B27	NULL
subtypes	NULL
present	NULL
the	NULL
same	NULL
immunodominant	NULL
Epstein-Barr	NULL
virus	NULL
peptide	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

178:879-887	NULL
.	NULL

11	NULL
.	NULL

Brossart	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
M.	NULL
J.	NULL
Bevan	NULL
.	NULL

1997	NULL
.	NULL

Presentation	NULL
of	NULL
exogenous	NULL
protein	NULL
antigens	NULL
on	NULL
major	NULL
histocompatability	NULL
complex	NULL
class	NULL
I	NULL
molecules	NULL
by	NULL
dendritic	NULL
cells	NULL
:	NULL
pathway	NULL
of	NULL
presentation	NULL
and	NULL
regulation	NULL
by	NULL
cytokines	NULL
.	NULL

Blood	NULL
90:1594-1599	NULL
.	NULL

12	NULL
.	NULL

Brossart	NULL
,	NULL
P.	NULL
,	NULL
A.	NULL
W.	NULL
Goldrath	NULL
,	NULL
E.	NULL
A.	NULL
Butz	NULL
,	NULL
S.	NULL
Martin	NULL
,	NULL
and	NULL
M.	NULL
J.	NULL
Bevan	NULL
.	NULL

1997	NULL
.	NULL

Virus-mediated	NULL
delivery	NULL
of	NULL
antigenic	NULL
epitopes	NULL
into	NULL
dendritic	NULL
cells	NULL
as	NULL
a	NULL
means	NULL
to	NULL
induce	NULL
CTL	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

158:3270-3276	NULL
.	NULL

13	NULL
.	NULL

Burrows	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
S.	NULL
L.	NULL
Silins	NULL
,	NULL
D.	NULL
J.	NULL
Moss	NULL
,	NULL
R.	NULL
Khanna	NULL
,	NULL
I.	NULL
S.	NULL
Misko	NULL
,	NULL
and	NULL
V.	NULL
P.	NULL
Argaet	NULL
.	NULL

1995	NULL
.	NULL

T	NULL
cell	NULL
receptor	NULL
repertoire	NULL
for	NULL
a	NULL
viral	NULL
epitope	NULL
in	NULL
humans	NULL
is	NULL
diversified	NULL
by	NULL
tolerance	NULL
to	NULL
a	NULL
background	NULL
major	NULL
histocompatibility	NULL
complex	NULL
antigen	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

182:1703-1715	NULL
.	NULL

14	NULL
.	NULL

Callan	NULL
,	NULL
M.	NULL
F.	NULL
C.	NULL
,	NULL
L.	NULL
Tan	NULL
,	NULL
N.	NULL
Aunels	NULL
,	NULL
G.	NULL
S.	NULL
Ogg	NULL
,	NULL
J.	NULL
D.	NULL
K.	NULL
Wilson	NULL
,	NULL
C.	NULL
A.	NULL
O'Callaghan	NULL
,	NULL
N.	NULL
Steven	NULL
,	NULL
A.	NULL
J.	NULL
McMichael	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
.	NULL

1998	NULL
.	NULL

Direct	NULL
visualization	NULL
of	NULL
antigen-specific	NULL
CD8	NULL
(	NULL
+	NULL
)	NULL
T	NULL
cells	NULL
during	NULL
the	NULL
primary	NULL
immune	NULL
response	NULL
to	NULL
Epstein-Barr	NULL
virus	NULL
in	NULL
vivo	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

187:1395-1402	NULL
.	NULL

15	NULL
.	NULL

Caux	NULL
,	NULL
C.	NULL
,	NULL
C.	NULL
Dezutterdambuyant	NULL
,	NULL
D.	NULL
Schmitt	NULL
,	NULL
and	NULL
J.	NULL
Banchereau	NULL
.	NULL

1992	NULL
.	NULL

GM-CSF	NULL
and	NULL
TNF-Alpha	NULL
co-operate	NULL
in	NULL
the	NULL
generation	NULL
of	NULL
dendritic	NULL
Langerhans	NULL
cells	NULL
.	NULL

Nature	NULL
360:258-261	NULL
.	NULL

16	NULL
.	NULL

Celluzzi	NULL
,	NULL
C.	NULL
,	NULL
J.	NULL
I	NULL
Mayordomo	NULL
,	NULL
W.	NULL
J.	NULL
Storkus	NULL
,	NULL
M.	NULL
T.	NULL
Lotze	NULL
,	NULL
and	NULL
L.	NULL
D.	NULL
Falo	NULL
.	NULL

1996	NULL
.	NULL

Peptide-pulsed	NULL
dendritic	NULL
cells	NULL
induce	NULL
antigen-specific	NULL
,	NULL
CTL-mediated	NULL
protective	NULL
tumor-immunity	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

183:283-287	NULL
.	NULL

17	NULL
.	NULL

Condon	NULL
,	NULL
C.	NULL
,	NULL
S.	NULL
C.	NULL
Watkins	NULL
,	NULL
C.	NULL
Celluzzi	NULL
,	NULL
K.	NULL
Thompson	NULL
,	NULL
and	NULL
L.	NULL
D.	NULL
Falo	NULL
.	NULL

1996	NULL
.	NULL

DNA-based	NULL
immunisation	NULL
by	NULL
in	NULL
vivo	NULL
transfection	NULL
of	NULL
dendritic	NULL
cells	NULL
.	NULL

Nat	NULL
.	NULL

Med	NULL
.	NULL

21122-1128	NULL
.	NULL

18.	NULL
de	NULL
Campos-Lima	NULL
,	NULL
P.-O	NULL
.	NULL

,	NULL
V.	NULL
Levitsky	NULL
,	NULL
J.	NULL
Brooks	NULL
,	NULL
S.	NULL
P.	NULL
Lee	NULL
,	NULL
L.	NULL
F.	NULL
Hu	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
,	NULL
and	NULL
M.	NULL
G.	NULL
Masucci	NULL
.	NULL

1994	NULL
.	NULL

T	NULL
cell	NULL
responses	NULL
and	NULL
virus	NULL
evolution	NULL
:	NULL
Loss	NULL
of	NULL
HLA	NULL
All-restricted	NULL
CTL	NULL
epitopes	NULL
in	NULL
Epstein-Barr	NULL
virus	NULL
isolates	NULL
from	NULL
high	NULL
A1l-positive	NULL
populations	NULL
by	NULL
selective	NULL
mutation	NULL
of	NULL
anchor	NULL
residues	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

179:1297-1305	NULL
.	NULL

19	NULL
.	NULL

Gratama	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
M.	NULL
M.	NULL
Zutter	NULL
,	NULL
J.	NULL
Minarovits	NULL
,	NULL
M.	NULL
A.	NULL
P.	NULL
Oosterveer	NULL
,	NULL
E.	NULL
D.	NULL
Thomas	NULL
,	NULL
G.	NULL
Klein	NULL
,	NULL
and	NULL
I.	NULL
Ernberg	NULL
.	NULL

1991	NULL
.	NULL

Expression	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
growth-transformation-associated	NULL
proteins	NULL
in	NULL
lymphoproliferations	NULL
of	NULL
bone-marrow	NULL
transplant	NULL
recipients	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
47:188-192	NULL
.	NULL

20	NULL
.	NULL

Hogan	NULL
,	NULL
K.	NULL
T.	NULL
,	NULL
N.	NULL
Shimojo	NULL
,	NULL
S.	NULL
F.	NULL
Walk	NULL
,	NULL
V.	NULL
H.	NULL
Engelhard	NULL
,	NULL
W.	NULL
L.	NULL
Maloy	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
Coligan	NULL
.	NULL

1988	NULL
.	NULL

Mutations	NULL
in	NULL
the	NULL
alpha-2	NULL
helix	NULL
of	NULL
HLA-A2	NULL
affect	NULL
presentation	NULL
but	NULL
do	NULL
not	NULL
inhibit	NULL
binding	NULL
of	NULL
influenza-virus	NULL
matrix	NULL
peptide	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

168:725-736	NULL
.	NULL

21	NULL
.	NULL

Inaba	NULL
,	NULL
K.	NULL
,	NULL
M.	NULL
Inaba	NULL
,	NULL
M.	NULL
Naito	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Steinman	NULL
.	NULL

1993	NULL
.	NULL

Dendritic	NULL
cell	NULL
progenitors	NULL
phagocytose	NULL
particulates	NULL
,	NULL
including	NULL
bacillus-calmette-guerin	NULL
or-ganisms	NULL
,	NULL
and	NULL
sensitise	NULL
mice	NULL
to	NULL
mycobacterial	NULL
antigens	NULL
in	NULL
vivo	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

178:479-488	NULL
.	NULL

22	NULL
.	NULL

Khanna	NULL
,	NULL
R.	NULL
,	NULL
S.	NULL
R.	NULL
Burrows	NULL
,	NULL
M.	NULL
G.	NULL
Kurilla	NULL
,	NULL
C.	NULL
A.	NULL
Jacob	NULL
,	NULL
I	NULL
S.	NULL
Misko	NULL
,	NULL
T.	NULL
B.	NULL
Sculley	NULL
,	NULL
E.	NULL
Kieff	NULL
,	NULL
and	NULL
D.	NULL
J.	NULL
Moss	NULL
.	NULL

1992	NULL
.	NULL

Localisation	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
cytotoxic	NULL
T	NULL
cell	NULL
epitopes	NULL
using	NULL
recombinant	NULL
vaccinia	NULL
:	NULL
implications	NULL
for	NULL
vaccine	NULL
development	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

176:169-178	NULL
.	NULL

23	NULL
.	NULL

Lee	NULL
,	NULL
S.	NULL
P.	NULL
,	NULL
S.	NULL
Morgan	NULL
,	NULL
J.	NULL
Skinner	NULL
,	NULL
W.	NULL
A.	NULL
Thomas	NULL
,	NULL
S.	NULL
R.	NULL
Jones	NULL
,	NULL
J.	NULL
Sutton	NULL
,	NULL
R.	NULL
Khanna	NULL
,	NULL
H.	NULL
C.	NULL
Whittle	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
.	NULL

1995	NULL
.	NULL

Epstcin-Barr	NULL
virus	NULL
isolates	NULL
with	NULL
the	NULL
major	NULL
HLA	NULL
B35.01-restricted	NULL
cytotoxic	NULL
T-lymphocyte	NULL
epitope	NULL
are	NULL
prevalent	NULL
in	NULL
a	NULL
highly	NULL
B35.01-positive	NULL
African	NULL
population	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

25:102-110	NULL
.	NULL

23a.Lee	NULL
,	NULL
S.	NULL
P.	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
.	NULL

Unpublished	NULL
observations	NULL
.	NULL

24	NULL
.	NULL

Lee	NULL
,	NULL
S.	NULL
P.	NULL
,	NULL
R.	NULL
J.	NULL
Tierney	NULL
,	NULL
W.	NULL
A.	NULL
Thomas	NULL
,	NULL
J.	NULL
M.	NULL
Brooks	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
.	NULL

1997	NULL
.	NULL

Conserved	NULL
cytotoxic	NULL
T	NULL
lymphocyte	NULL
(	NULL
CTL	NULL
)	NULL
epitopes	NULL
within	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
latent	NULL
membrane	NULL
protein	NULL
2	NULL
,	NULL
a	NULL
potential	NULL
target	NULL
for	NULL
CTL-based	NULL
342	NULL
25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

REDCHENKO	NULL
AND	NULL
RICKINSON	NULL
tumour	NULL
therapy	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

158:3325-3334	NULL
.	NULL

Levitskaya	NULL
,	NULL
J.	NULL
,	NULL
M.	NULL
Coram	NULL
,	NULL
V.	NULL
Levitsky	NULL
,	NULL
S.	NULL
Imreb	NULL
,	NULL
P.	NULL
M.	NULL
Steigerwald-Mullen	NULL
,	NULL
G.	NULL
Klein	NULL
,	NULL
M.	NULL
G.	NULL
Kurilla	NULL
,	NULL
and	NULL
M.	NULL
G.	NULL
Masucci	NULL
.	NULL

1995	NULL
.	NULL

Inhibition	NULL
of	NULL
antigen	NULL
processing	NULL
by	NULL
the	NULL
internal	NULL
repeat	NULL
region	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
nuclear	NULL
antigen	NULL
1	NULL
.	NULL

Nature	NULL
375:685-688	NULL
.	NULL

Levitskaya	NULL
,	NULL
J.	NULL
,	NULL
A.	NULL
Sharipo	NULL
,	NULL
A.	NULL
Leonchiks	NULL
,	NULL
A.	NULL
Ciechanover	NULL
,	NULL
and	NULL
M.	NULL
G.	NULL
Ma-sueci	NULL
.	NULL

1997	NULL
.	NULL

Inhibition	NULL
of	NULL
ubiquitin/proteasome-dependent	NULL
protein	NULL
degradation	NULL
by	NULL
the	NULL
Gly-Ala	NULL
repeat	NULL
domain	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
nuclear	NULL
antigen	NULL
1	NULL
.	NULL

Proc	NULL
.	NULL

Nat	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94:12616-12621	NULL
.	NULL

Ludewig	NULL
,	NULL
B.	NULL
,	NULL
S.	NULL
Ehl	NULL
,	NULL
U.	NULL
Karrer	NULL
,	NULL
B.	NULL
Odermatt	NULL
,	NULL
H.	NULL
Hengartner	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Zinkernagel	NULL
.	NULL

1998	NULL
.	NULL

Dendritic	NULL
cells	NULL
efficiently	NULL
induce	NULL
protective	NULL
antiviral	NULL
immunity	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

72:3812-3818	NULL
.	NULL

Macatonia	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
S.	NULL
Patterson	NULL
,	NULL
and	NULL
S.	NULL
C.	NULL
Knight	NULL
.	NULL

1991	NULL
.	NULL

Primary	NULL
proliferative	NULL
and	NULL
cytotoxic	NULL
T	NULL
cell	NULL
responses	NULL
to	NULL
HIV	NULL
induced	NULL
in	NULL
vitro	NULL
by	NULL
human	NULL
dendritic	NULL
cells	NULL
.	NULL

Immunology	NULL
74:399-406	NULL
.	NULL

Macatonia	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
P.	NULL
M.	NULL
Taylor	NULL
,	NULL
S.	NULL
C.	NULL
Knight	NULL
,	NULL
and	NULL
B	NULL
.	NULL

A.	NULL
Askonas	NULL
.	NULL

1989	NULL
.	NULL

Primary	NULL
stimulation	NULL
by	NULL
dendritic	NULL
cells	NULL
induces	NULL
antiviral	NULL
proliferative	NULL
and	NULL
cytotoxic	NULL
T	NULL
cell	NULL
responses	NULL
in	NULL
vitro	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

169:1255-1264	NULL
.	NULL

Martinon	NULL
,	NULL
F.	NULL
,	NULL
E.	NULL
Gomard	NULL
,	NULL
C.	NULL
Hannoun	NULL
,	NULL
and	NULL
J.	NULL
P.	NULL
Levy	NULL
.	NULL

1990	NULL
.	NULL

In	NULL
vitro	NULL
human	NULL
cytotoxic	NULL
T	NULL
cell	NULL
responses	NULL
against	NULL
influenza	NULL
A	NULL
virus	NULL
can	NULL
be	NULL
induced	NULL
and	NULL
selected	NULL
by	NULL
synthetic	NULL
peptides	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

20:2171-2176	NULL
.	NULL

Mayordomo	NULL
,	NULL
J.	NULL
I.	NULL
,	NULL
T.	NULL
Zorina	NULL
,	NULL
W.	NULL
J.	NULL
Storkus	NULL
,	NULL
L.	NULL
Zitvogel	NULL
,	NULL
C.	NULL
Celluzzi	NULL
,	NULL
and	NULL
L.	NULL
D.	NULL
Falo	NULL
.	NULL

1995	NULL
.	NULL

Bone	NULL
marrow-derived	NULL
dendritic	NULL
cells	NULL
pulsed	NULL
with	NULL
synthetic	NULL
tumor	NULL
peptides	NULL
elicit	NULL
protective	NULL
and	NULL
therapeutic	NULL
anti-tumor	NULL
immunity	NULL
.	NULL

Nat	NULL
.	NULL

Med	NULL
.	NULL

1:1297-1302	NULL
.	NULL

Mehtadamani	NULL
,	NULL
A.	NULL
,	NULL
S.	NULL
Markowicz	NULL
,	NULL
and	NULL
E.	NULL
G.	NULL
Engleman	NULL
.	NULL

1994	NULL
.	NULL

Generation	NULL
of	NULL
antigen-specific	NULL
CD8*	NULL
CTLs	NULL
from	NULL
naive	NULL
precursors	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

153:996-1003	NULL
.	NULL

Murray	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
M.	NULL
G.	NULL
Kurilla	NULL
,	NULL
J.	NULL
M.	NULL
Brooks	NULL
,	NULL
W.	NULL
A.	NULL
Thomas	NULL
,	NULL
M.	NULL
Rowe	NULL
,	NULL
E.	NULL
Kieff	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
.	NULL

1992	NULL
.	NULL

Identification	NULL
of	NULL
target	NULL
antigens	NULL
for	NULL
the	NULL
human	NULL
cytotoxic	NULL
T	NULL
cell	NULL
response	NULL
to	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
:	NULL
implications	NULL
for	NULL
the	NULL
immune	NULL
control	NULL
of	NULL
EBV-positive	NULL
malignancies	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

176:157-168	NULL
.	NULL

Nestle	NULL
,	NULL
F.	NULL
O.	NULL
,	NULL
S.	NULL
Alijagic	NULL
,	NULL
M.	NULL
Gilliet	NULL
,	NULL
Y.	NULL
S.	NULL
Sun	NULL
,	NULL
S.	NULL
Grabbe	NULL
,	NULL
R.	NULL
Dummer	NULL
,	NULL
G.	NULL
Burg	NULL
,	NULL
and	NULL
D.	NULL
Schadendorf	NULL
.	NULL

1998	NULL
.	NULL

Vaccination	NULL
of	NULL
melanoma	NULL
patients	NULL
with	NULL
peptide-	NULL
or	NULL
tumour	NULL
lysate-pulsed	NULL
dendritic	NULL
cells	NULL
.	NULL

Nat	NULL
.	NULL

Med	NULL
.	NULL

4:328-332	NULL
.	NULL

Paglia	NULL
,	NULL
P.	NULL
,	NULL
C.	NULL
Chiodoni	NULL
,	NULL
M.	NULL
Rodolfo	NULL
,	NULL
and	NULL
M.	NULL
P.	NULL
Colombo	NULL
.	NULL

1996	NULL
.	NULL

Murine	NULL
dendritic	NULL
cells	NULL
loaded	NULL
in	NULL
vitro	NULL
with	NULL
soluble	NULL
protein	NULL
prime	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
against	NULL
tumor	NULL
antigen	NULL
in	NULL
vivo	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

183:317-322	NULL
.	NULL

Plebanski	NULL
,	NULL
M.	NULL
,	NULL
C.	NULL
E.	NULL
M.	NULL
Allsopp	NULL
,	NULL
M.	NULL
Aidoo	NULL
,	NULL
H.	NULL
Reyburn	NULL
,	NULL
and	NULL
A.	NULL
V.	NULL
S.	NULL
Hill	NULL
.	NULL

1995	NULL
.	NULL

Induction	NULL
of	NULL
peptide-specific	NULL
primary	NULL
cytotoxic	NULL
T-lymphocyte	NULL
responses	NULL
from	NULL
human	NULL
peipheral	NULL
blood	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

25:1783-1787	NULL
.	NULL

Rickinson	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1996	NULL
.	NULL

Epstein-Barr	NULL
Virus	NULL
,	NULL
p.	NULL
2397-2446	NULL
.	NULL

In	NULL
B.	NULL
N.	NULL
Fields	NULL
,	NULL
D.	NULL
M.	NULL
Knipe	NULL
,	NULL
and	NULL
P.	NULL
M.	NULL
Howley	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Fields	NULL
virology	NULL
.	NULL

Lippin-cott-Raven	NULL
,	NULL
Philadelphia	NULL
,	NULL
Pa.	NULL
Rickinson	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
,	NULL
and	NULL
D.	NULL
J.	NULL
Moss	NULL
.	NULL

1997	NULL
.	NULL

Human	NULL
cytotoxic	NULL
T	NULL
lymphocyte	NULL
responses	NULL
to	NULL
Epstein-Barr	NULL
virus	NULL
infection	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

15:405-431	NULL
.	NULL

Rivoltini	NULL
,	NULL
L.	NULL
,	NULL
Y.	NULL
Kawakami	NULL
,	NULL
K.	NULL
Sakaguchi	NULL
,	NULL
S.	NULL
Southwood	NULL
,	NULL
A.	NULL
Sette	NULL
,	NULL
P.	NULL
F.	NULL
Robbins	NULL
,	NULL
F.	NULL
M.	NULL
Marincola	NULL
,	NULL
M.	NULL
L.	NULL
Salgaller	NULL
,	NULL
Y.	NULL
R.	NULL
Yannelli	NULL
,	NULL
E.	NULL
Appella	NULL
,	NULL
and	NULL
S.	NULL
A.	NULL
Rosenberg	NULL
.	NULL

1995	NULL
.	NULL

Induction	NULL
of	NULL
tumor-reactive	NULL
CTL	NULL
from	NULL
peripheral	NULL
blood	NULL
and	NULL
tumor-infiltrating	NULL
lymphocytes	NULL
of	NULL
melanoma	NULL
patients	NULL
by	NULL
in	NULL
vitro	NULL
stimulation	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

154:2257-2265	NULL
.	NULL

Romani	NULL
,	NULL
N.	NULL
,	NULL
S.	NULL
Gruner	NULL
,	NULL
D.	NULL
Brang	NULL
,	NULL
E.	NULL
Kampgen	NULL
,	NULL
A.	NULL
Lenz	NULL
,	NULL
B.	NULL
Trockenbacher	NULL
,	NULL
G.	NULL
Konwalinka	NULL
,	NULL
P.	NULL
O.	NULL
Fritsch	NULL
,	NULL
R.	NULL
M.	NULL
Steinman	NULL
,	NULL
and	NULL
G.	NULL
Schuler	NULL
.	NULL

1994	NULL
.	NULL

Proliferating	NULL
dendritic	NULL
cell	NULL
progenitors	NULL
in	NULL
human	NULL
blood	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

180:83-93	NULL
.	NULL

Romani	NULL
,	NULL
N.	NULL
,	NULL
D.	NULL
Reider	NULL
,	NULL
M.	NULL
Heuer	NULL
,	NULL
S.	NULL
Ebner	NULL
,	NULL
E.	NULL
Kampgen	NULL
,	NULL
B.	NULL
Kibl	NULL
,	NULL
D.	NULL
Nied-erwieser	NULL
,	NULL
and	NULL
G.	NULL
Schuler	NULL
.	NULL

1996	NULL
.	NULL

Generation	NULL
of	NULL
mature	NULL
dendritic	NULL
cells	NULL
from	NULL
human	NULL
blood	NULL
:	NULL
an	NULL
improved	NULL
method	NULL
with	NULL
special	NULL
regard	NULL
to	NULL
clinical	NULL
applica-bility	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

Methods	NULL
196:137-151	NULL
.	NULL

Rooney	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
C.	NULL
A.	NULL
Smith	NULL
,	NULL
C.	NULL
Y.	NULL
C.	NULL
Ng	NULL
,	NULL
S.	NULL
Loftin	NULL
,	NULL
C.	NULL
Li	NULL
,	NULL
R.	NULL
A.	NULL
Krance	NULL
,	NULL
M.	NULL
K.	NULL
Brenner	NULL
,	NULL
and	NULL
H.	NULL
E.	NULL
Heslop	NULL
.	NULL

1995	NULL
.	NULL

Use	NULL
of	NULL
gene-modified	NULL
virus-specific	NULL
T	NULL
lymphocytes	NULL
to	NULL
control	NULL
Epstein-Barr	NULL
virus-related	NULL
lymphoproliferation	NULL
.	NULL

Lancet	NULL
345:9-13	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

J.	NULL
Virou	NULL
.	NULL

Sallusto	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
A.	NULL
Lanzavecchi	NULL
.	NULL

1994	NULL
.	NULL

Efficient	NULL
presentation	NULL
of	NULL
soluble	NULL
antigen	NULL
by	NULL
cultured	NULL
human	NULL
dendritic	NULL
cells	NULL
is	NULL
maintained	NULL
by	NULL
granulocyte-macrophage	NULL
colony	NULL
stimulating	NULL
factor	NULL
plus	NULL
interleukin-4	NULL
and	NULL
down-regulated	NULL
by	NULL
tumor-necrosis-factor-alpha	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

179:1109-1118	NULL
.	NULL

Schuler	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Steinman	NULL
.	NULL

1997	NULL
.	NULL

Dendritic	NULL
cells	NULL
as	NULL
adjuvants	NULL
for	NULL
immune-mediated	NULL
resistance	NULL
to	NULL
tumors	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

186:1183-1187	NULL
.	NULL

Scotet	NULL
,	NULL
E.	NULL
,	NULL
J.	NULL
David-Ameline	NULL
,	NULL
M.-A	NULL
.	NULL

Peyrat	NULL
,	NULL
A.	NULL
Moreau-Aubry	NULL
,	NULL
D.	NULL
Pinczon	NULL
,	NULL
A.	NULL
Lim	NULL
,	NULL
J	NULL
.	NULL

Even	NULL
,	NULL
G.	NULL
Semana	NULL
,	NULL
J.	NULL
M.	NULL
Berthelot	NULL
,	NULL
R.	NULL
Breathnach	NULL
,	NULL
M.	NULL
Bonneville	NULL
,	NULL
and	NULL
E.	NULL
Houssaint	NULL
.	NULL

1996	NULL
.	NULL

T	NULL
cell	NULL
response	NULL
to	NULL
Epstein-Barr	NULL
virus	NULL
transactivators	NULL
in	NULL
chronic	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

184:1791-1800	NULL
.	NULL

Shen	NULL
,	NULL
Z.	NULL
H.	NULL
,	NULL
G.	NULL
Reznikoff	NULL
,	NULL
G.	NULL
Dranoff	NULL
,	NULL
and	NULL
K.	NULL
L.	NULL
Rock	NULL
.	NULL

1997	NULL
.	NULL

Cloned	NULL
dendritic	NULL
cells	NULL
can	NULL
present	NULL
exogenous	NULL
antigens	NULL
on	NULL
both	NULL
MHC	NULL
class	NULL
I	NULL
and	NULL
class	NULL
II	NULL
molecules	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

158:2723-2730	NULL
.	NULL

Song	NULL
,	NULL
W.	NULL
,	NULL
H.	NULL
L.	NULL
Kong	NULL
,	NULL
H.	NULL
Carpenter	NULL
,	NULL
H.	NULL
Torii	NULL
,	NULL
R.	NULL
Granstein	NULL
,	NULL
S.	NULL
Rafii	NULL
,	NULL
M.	NULL
A.	NULL
S.	NULL
Moore	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Crystal	NULL
.	NULL

1997	NULL
.	NULL

Dendritic	NULL
cells	NULL
genetically	NULL
modified	NULL
with	NULL
an	NULL
adenovirus	NULL
vector	NULL
encoding	NULL
the	NULL
cDNA	NULL
for	NULL
a	NULL
model	NULL
antigen	NULL
induce	NULL
protective	NULL
and	NULL
therapeutic	NULL
anti-tumor	NULL
immunity	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

186:1247-1256	NULL
.	NULL

Specht	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
G.	NULL
Wang	NULL
,	NULL
M.	NULL
T.	NULL
Do	NULL
,	NULL
J.	NULL
S.	NULL
Lam	NULL
,	NULL
R.	NULL
E.	NULL
Royal	NULL
,	NULL
M.	NULL
E.	NULL
Reeves	NULL
,	NULL
S.	NULL
A.	NULL
Rosenberg	NULL
,	NULL
and	NULL
P.	NULL
Hwu	NULL
.	NULL

1997	NULL
.	NULL

Dendritic	NULL
cells	NULL
retrovirally	NULL
transduced	NULL
with	NULL
a	NULL
model	NULL
antigen	NULL
gene	NULL
are	NULL
therapeutically	NULL
effective	NULL
against	NULL
established	NULL
pulmonary	NULL
metastases	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

186:1213-1221	NULL
.	NULL

Steven	NULL
,	NULL
N.	NULL
M.	NULL
,	NULL
N.	NULL
Annels	NULL
,	NULL
A.	NULL
Kumar	NULL
,	NULL
A.	NULL
Leese	NULL
,	NULL
M.	NULL
G.	NULL
Kurilla	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
.	NULL

1997	NULL
.	NULL

Immediate	NULL
early	NULL
and	NULL
early	NULL
lytic	NULL
cycle	NULL
proteins	NULL
are	NULL
frequent	NULL
targets	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus-induced	NULL
cytotoxic	NULL
T	NULL
cell	NULL
response	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

185:1605-1617.	NULL
.	NULL

Steven	NULL
,	NULL
N.	NULL
M.	NULL
,	NULL
A.	NULL
M.	NULL
Leese	NULL
,	NULL
N.	NULL
Annels	NULL
,	NULL
S.	NULL
Lee	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rickinson	NULL
.	NULL

1996	NULL
.	NULL

Epitope	NULL
focusing	NULL
in	NULL
the	NULL
primary	NULL
cytotoxic	NULL
T-cell	NULL
response	NULL
to	NULL
Epstein-Barr	NULL
virus	NULL
and	NULL
its	NULL
relationship	NULL
to	NULL
T-cell	NULL
memory	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

184:1801-1813	NULL
.	NULL

Thomas	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
N.	NULL
Hotchin	NULL
,	NULL
M.	NULL
J.	NULL
Allday	NULL
,	NULL
M.	NULL
Yacoub	NULL
,	NULL
and	NULL
D.	NULL
H.	NULL
Crawford	NULL
.	NULL

1990	NULL
.	NULL

Immunohistology	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
associated	NULL
antigens	NULL
in	NULL
B	NULL
cell	NULL
disorders	NULL
from	NULL
immunocompromised	NULL
individuals	NULL
.	NULL

Transplantation	NULL
49:944-953	NULL
.	NULL

Tjandrawan	NULL
,	NULL
T.	NULL
,	NULL
D.	NULL
M.	NULL
Martin	NULL
,	NULL
M.	NULL
J.	NULL
Maeurer	NULL
,	NULL
C.	NULL
Castelli	NULL
,	NULL
M.	NULL
T.	NULL
Lotze	NULL
,	NULL
and	NULL
W.	NULL
J.	NULL
Storkus	NULL
.	NULL

1998	NULL
.	NULL

Autologous	NULL
human	NULL
dendriphages	NULL
pulsed	NULL
with	NULL
synthetic	NULL
or	NULL
natural	NULL
tumor	NULL
peptides	NULL
elicit	NULL
tumor-specific	NULL
CTLs	NULL
in	NULL
vitro	NULL
.	NULL

J.	NULL
Immunother	NULL
.	NULL

21:149-157	NULL
.	NULL

Tsai	NULL
,	NULL
V.	NULL
,	NULL
S.	NULL
Southwood	NULL
,	NULL
J.	NULL
Sidney	NULL
,	NULL
K.	NULL
Sakaguchi	NULL
,	NULL
Y.	NULL
Kawakami	NULL
,	NULL
E.	NULL
Appella	NULL
,	NULL
A.	NULL
Sette	NULL
,	NULL
and	NULL
E.	NULL
Celis	NULL
.	NULL

1997	NULL
.	NULL

Identification	NULL
of	NULL
subdominant	NULL
CTL	NULL
epitopes	NULL
of	NULL
the	NULL
GP100	NULL
melanoma-associated	NULL
tumor	NULL
antigen	NULL
by	NULL
primary	NULL
in	NULL
vitro	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

158:1796-1802	NULL
.	NULL

Tuting	NULL
,	NULL
T.	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
DeLeo	NULL
,	NULL
M.	NULL
T.	NULL
Lotze	NULL
,	NULL
and	NULL
W.	NULL
J.	NULL
Storkus	NULL
.	NULL

1997	NULL
.	NULL

Genetically	NULL
modified	NULL
bone	NULL
marrow-derived	NULL
dendritic	NULL
cells	NULL
expressing	NULL
tumor-associated	NULL
viral	NULL
or	NULL
``	NULL
self	NULL
``	NULL
antigens	NULL
induce	NULL
anti-tumor	NULL
immunity	NULL
in	NULL
vivo	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

27:2702-2707	NULL
.	NULL

Vanderbruggen	NULL
,	NULL
P.	NULL
,	NULL
J.	NULL
Bastin	NULL
,	NULL
T.	NULL
Gajewki	NULL
,	NULL
P.	NULL
G.	NULL
Coulie	NULL
,	NULL
P.	NULL
Boel	NULL
,	NULL
C.	NULL
Desmet	NULL
,	NULL
C.	NULL
Traversari	NULL
,	NULL
A.	NULL
Townsend	NULL
,	NULL
and	NULL
T.	NULL
Boon	NULL
.	NULL

1994	NULL
.	NULL

A	NULL
peptide	NULL
encoded	NULL
by	NULL
human	NULL
gene	NULL
MAGE-3	NULL
and	NULL
presented	NULL
by	NULL
HLA-A2	NULL
induces	NULL
cytolytic	NULL
T	NULL
lymphocytes	NULL
that	NULL
recognise	NULL
tumor	NULL
cells	NULL
expressing	NULL
MAGE-3	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

24:3038-3043	NULL
.	NULL

Visseren	NULL
,	NULL
M.	NULL
J.	NULL
W.	NULL
,	NULL
A.	NULL
Vanelsas	NULL
,	NULL
E.	NULL
I.	NULL
H.	NULL
Vandervoort	NULL
,	NULL
M.	NULL
E.	NULL
Ressing	NULL
,	NULL
W.	NULL
M.	NULL
Kast	NULL
,	NULL
P.	NULL
I.	NULL
Schrier	NULL
,	NULL
and	NULL
C.	NULL
J.	NULL
M.	NULL
Melief	NULL
.	NULL

1995	NULL
.	NULL

CTL-specific	NULL
for	NULL
the	NULL
tyrosinase	NULL
auto-antigen	NULL
can	NULL
be	NULL
induced	NULL
from	NULL
healthy	NULL
donor	NULL
blood	NULL
to	NULL
lyse	NULL
melanoma	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

154:3991-3998	NULL
.	NULL

Yang	NULL
,	NULL
S.	NULL
X.	NULL
,	NULL
T.	NULL
L.	NULL
Darrow	NULL
,	NULL
C.	NULL
E.	NULL
Vervaert	NULL
,	NULL
and	NULL
H.	NULL
F.	NULL
Seigler	NULL
.	NULL

1997	NULL
.	NULL

Immu-notherapeutic	NULL
potential	NULL
of	NULL
tumor	NULL
antigen-pulsed	NULL
and	NULL
unpulsed	NULL
dendritic	NULL
cells	NULL
generated	NULL
from	NULL
murine	NULL
bone	NULL
marrow	NULL
.	NULL

Cell	NULL
.	NULL

Immunol	NULL
.	NULL

179:84-95	NULL
.	NULL

York	NULL
,	NULL
I	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
K.	NULL
I	NULL
.	NULL

Rock	NULL
.	NULL

1996	NULL
.	NULL

Antigen-processing	NULL
and	NULL
presentation	NULL
by	NULL
the	NULL
class	NULL
I	NULL
major	NULL
histocompatibility	NULL
complex	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

14:369-396	NULL
.	NULL

Zhou	NULL
,	NULL
L.	NULL
J.	NULL
,	NULL
R.	NULL
Schwarting	NULL
,	NULL
H.	NULL
M.	NULL
Smith	NULL
,	NULL
and	NULL
T.	NULL
F.	NULL
Tedder	NULL
.	NULL

1992	NULL
.	NULL

A	NULL
novel	NULL
cell	NULL
surface	NULL
molecule	NULL
expressed	NULL
by	NULL
human	NULL
interdigitating	NULL
reticulum	NULL
cells	NULL
,	NULL
Langerhans	NULL
cells	NULL
,	NULL
and	NULL
activated	NULL
lymphocytes	NULL
is	NULL
a	NULL
new	NULL
member	NULL
of	NULL
the	NULL
Ig	NULL
super-family	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

149:735-742	NULL
.	NULL

